References

Ref. 1. NCI Surveillance, Epidemiology, and End Results Program. NCI SEER*Explorer. Accessed: June 30, 2026. Available from: https://seer.cancer.gov/statistics-network/explorer/application.html

Ref. 2. Siegel RL, et al. (2026) CA Cancer J Clin, 76: e70043. Available from: https://doi.org/10.3322/caac.70043

Ref. 3. Shiels MS, et al. (2025) J Natl Cancer Inst, 117: 2089. Available from: https://doi.org/10.1093/jnci/djaf192

Ref. 4. Caswell-Jin JL, et al. (2024) JAMA, 331: 233. Available from: https://doi.org/10.1001/jama.2023.25881

Ref. 5. Siegel RL, et al. (2026) JAMA. 335: 632. Available from: https://doi.org/10.1001/jama.2025.25467

Ref. 6. Siegel RL, et al. (2026) CA: A Cancer Journal for Clinicians, 76: e70067. Available from: https://doi.org/10.3322/caac.70067

Ref. 7. Henley SJ, et al. (2026) JAMA Oncol. Available from: https://doi.org/10.1001/jamaoncol.2026.1199

Ref. 8. National Program of Cancer Registries and Surveillance, Epidemiology and End Results Program SEER*Stat Database: NPCR and SEER Incidence – U.S. Cancer Statistics Public Use Research Database, 2025 Submission (2001-2023). United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Released June 2025. Accessed: June 30, 2026. Available from: https://www.cdc.gov/united-states-cancer-statistics/public-use/

Ref. 9. Howlader N, et al. (2023) Cancer Epidemiol Biomarkers Prev, 32: 744. Available from: https://doi.org/10.1158/1055-9965.EPI-22-1171

Ref. 10. Centers for Disease Control and Prevention. United States Cancer Cases and Death Statistics At a Glance. Accessed: June 30, 2026. Available from: https://gis.cdc.gov/cancer/USCS/#/

Ref. 11. Brown ZJ, et al. (2023) JAMA Surg, 158: 410. Available from: https://doi.org/10.1001/jamasurg.2022.7989

Ref. 12. SEER*Stat Database: Incidence – SEER Research Plus Limited-Field Data, 21 Registries (excl IL), Nov 2025 Sub (2000-2023) – Linked To County Attributes – Total U.S., 1969-2024 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2026, based on the November 2025 submission. Accessed: June 30, 2026. Available from: https://seer.cancer.gov/data/

Ref. 13. Wagle NS, et al. (2025) CA Cancer J Clin, 75: 308. Available from: https://doi.org/10.3322/caac.70011

Ref. 14. SEER*Stat Database: Incidence – SEER Research Data, 9 Registries, Nov 2020 Sub (1975-2018) – Linked To County Attributes – Time Dependent (1990-2018) Income/Rurality, 1969-2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2025, based on the November 2020 submission. Accessed: June 30, 2026. Available from: https://seer.cancer.gov/data/

Ref. 15. American Cancer Society. Cancer Facts and Figures 2026. Accessed: June 30, 2026. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf

Ref. 16. American Association for Cancer Research. AACR Cancer Disparities Progress Report 2026. Accessed: June 30, 2026. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2026/06/AACR_CDPR_2026.pdf

Ref. 17. LoPiccolo J, et al. (2024) Nat Rev Clin Oncol, 21: 121. Available from: https://doi.org/10.1038/s41571-023-00844-0

Ref. 18. Patel C, et al. (2026) J Clin Med, 15. Available from: https://doi.org/10.3390/jcm15041316

Ref. 19. Gupta A, et al. (2024) Cancer Epidemiol, 92: 102632. Available from: https://doi.org/10.1016/j.canep.2024.102632

Ref. 20. Taparra K, et al. (2024) JAMA Netw Open, 7: e2430975. Available from: https://doi.org/10.1001/jamanetworkopen.2024.30975

Ref. 21. SEERStat/NAACCR. SEERStat Database: NAACCR Incidence Data – CiNA Research Data, 2010-2022, Public Use (20 Age Groups) (which includes data from CDC’s National Program of Cancer Registries (NPCR), CCR’s Provincial and Territorial Registries, and the NCI’s Surveillance, Epidemiology and End Results (SEER) Registries), submitted December 2024. 2026

Ref. 22. SEERStat/SEER21. SEERStat Database: Incidence – SEER Research Plus Limited-Field Data, 21 Registries, November 2025 submission (2000-2023). 2026

Ref. 23. Schroeder EW, et al. (2025) Cancer Epidemiol Biomarkers Prev, 34: 2294. Available from: https://doi.org/10.1158/1055-9965.EPI-25-0567

Ref. 24. Hymel E, et al. (2025) Pediatrics, 155. Available from: https://doi.org/10.1542/peds.2024-069973

Ref. 25. Chang CE, et al. (2025) Cancer Causes Control, 36: 605. Available from: https://doi.org/10.1007/s10552-025-01964-x

Ref. 26. Cosby AG, et al. (2026) Br J Cancer, 134: 1468. Available from: https://doi.org/10.1038/s41416-026-03339-8

Ref. 27. Islami F, et al. (2026) J Natl Cancer Inst. Available from: https://doi.org/10.1093/jnci/djag047

Ref. 28. Chen JC, et al. (2024) JAMA Netw Open, 7: e2427755. Available from: https://doi.org/10.1001/jamanetworkopen.2024.27755

Ref. 29. Karanth S, et al. (2024) Cancer Causes Control, 35: 1063. Available from: https://doi.org/10.1007/s10552-024-01867-3

Ref. 30. Simone NL, et al. (2025) J Natl Cancer Inst Monogr, 2025: 153. Available from: https://doi.org/10.1093/jncimonographs/lgaf030

Ref. 31. Alvidrez J, et al. (2019) Am J Public Health, 109: S16. Available from: https://doi.org/10.2105/AJPH.2018.304883

Ref. 32. Asare M, et al. (2017) Oncol Nurs Forum, 44: 20. Available from: https://doi.org/10.1188/17.ONF.20-23

Ref. 33. Esteban C, et al. (2025) Int J Environ Res Public Health, 22. Available from: https://doi.org/10.3390/ijerph22070992

Ref. 34. Warnecke RB, et al. (2008) Am J Public Health, 98: 1608. Available from: https://doi.org/10.2105/AJPH.2006.102525

Ref. 35. Islami F, et al. (2025) Cancer, 131: e70073. Available from: https://doi.org/10.1002/cncr.70073

Ref. 36. American Cancer Society. Cancer Prevention & Early Detection Facts and Figures 2026. Accessed: June 30, 2026. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-prevention-and-early-detection-facts-and-figures/2026-cped-files/cped-2026-tables-and-figures.pdf

Ref. 37. Rolle LD, et al. (2025) JAMA Oncol, 11: 784. Available from: https://doi.org/10.1001/jamaoncol.2025.0230

Ref. 38. Dong W, et al. (2025) J Natl Compr Canc Netw, 24. Available from: https://doi.org/10.6004/jnccn.2025.7092

Ref. 39. Kwak M, et al. (2024) J Thorac Cardiovasc Surg, 168: 1235. Available from: https://doi.org/10.1016/j.jtcvs.2023.12.012

Ref. 40. Ajjawi I, et al. (2025) Breast Cancer Res Treat, 212: 299. Available from: https://doi.org/10.1007/s10549-025-07725-3

Ref. 41. Dennis MJ, et al. (2025) JCO Precis Oncol, 9: e2400449. Available from: https://doi.org/10.1200/PO-24-00449

Ref. 42. Zhang S, et al. (2026) Melanoma Manag, 13: 2629903. Available from: https://doi.org/10.1080/20450885.2026.2629903

Ref. 43. Abbas M, et al. (2026) JTCVS Open: 101830. Available from: https://doi.org/10.1016/j.xjon.2026.101830

Ref. 44. Liang J, et al. (2025) Am J Obstet Gynecol, 233: 186 e1. Available from: https://doi.org/10.1016/j.ajog.2025.02.032

Ref. 45. Nykaza I, et al. (2025) Lung Cancer, 206: 108661. Available from: https://doi.org/10.1016/j.lungcan.2025.108661

Ref. 46. Parikh-Patel A, et al. (2026) Am J Prev Med, 71: 108333. Available from: https://doi.org/10.1016/j.amepre.2026.108333

Ref. 47. Pilehvari A, et al. (2025) Breast Cancer Res Treat, 210: 575. Available from: https://doi.org/10.1007/s10549-024-07593-3

Ref. 48. NCI Childhood Cancer Data Initiative. NCI NCCR*Explorer. Accessed: June 30, 2026. Available from: https://nccrexplorer.ccdi.cancer.gov/application.html

Ref. 49. International Agency for Research on Cancer. Global Cancer Observatory. Accessed: June 30, 2026. Available from: http://globocan.iarc.fr/

Ref. 50. US Census Bureau. 2023 National Population Projections Tables. Accessed: June 30, 2026. Available from: https://www.census.gov/data/tables/2023/demo/popproj/2023-summary-tables.html

Ref. 51. Agaku I (2026) NEJM Evid, 5: EVIDpha2500339. Available from: https://doi.org/10.1056/EVIDpha2500339

Ref. 52. Murphy C, et al. (2025) JAMA, 334: 1836. Available from: https://doi.org/10.1001/jama.2025.17695

Ref. 53. Caswell DR, et al. (2026) Trends in Cancer, 12: 310. Available from: https://doi.org/10.1016/j.trecan.2025.12.009

Ref. 54. Yasinzai AQK, et al. (2026) JNCI: Journal of the National Cancer Institute, 118: 250. Available from: https://doi.org/10.1093/jnci/djaf304

Ref. 55. Andre F, et al. (2025) ESMO Open, 10: 105553. Available from: https://doi.org/10.1016/j.esmoop.2025.105553

Ref. 56. Shiels MS, et al. (2025) Cancer Discov, 15: 1363. Available from: https://doi.org/10.1158/2159-8290.CD-24-1678

Ref. 57. Chiao E, et al. (2025) Cancer Epidemiol Biomarkers Prev, 34: 1686. Available from: https://doi.org/10.1158/1055-9965.EPI-25-0040

Ref. 58. Koh B, et al. (2023) JAMA Netw Open, 6: e2328171. Available from: https://doi.org/10.1001/jamanetworkopen.2023.28171

Ref. 59. Chung DC, et al. (2024) N Engl J Med, 390: 973. Available from: https://doi.org/10.1056/NEJMoa2304714

Ref. 60. Seum T, et al. (2025) JAMA Intern Med, 185: 110. Available from: https://doi.org/10.1001/jamainternmed.2024.6149

Ref. 61. Sung H, et al. (2026) CA: A Cancer Journal for Clinicians, 76: e70090. Available from: https://doi.org/10.3322/caac.70090

Ref. 62. United Nations Development Programme. Human Development Index (HDI). Accessed: June 30, 2026. Available from: https://hdr.undp.org/data-center/human-development-index#/indicies/HDI

Ref. 63. United Nations Development Programme. Human Development Report 2023/2024 Technical Notes. Accessed: June 30, 2026. Available from: https://hdr.undp.org/sites/default/files/2023-24_HDR/hdr2023-24_technical_notes.pdf

Ref. 64. Adepoju P (2026) Lancet Oncol. Available from: https://doi.org/10.1016/S1470-2045(26)00138-5

Ref. 65. Atun R, et al. (2020) Lancet Oncol, 21: e185. Available from: https://doi.org/10.1016/S1470-2045(20)30022-X

Ref. 66. Bhakta N, et al. (2019) Lancet Oncol, 20: e42. Available from: https://doi.org/10.1016/S1470-2045(18)30761-7

Ref. 67. World Health Organization. CureAll framework: WHO Global Initiative for Childhood Cancer. Increasing Access, Advancing quality, Saving lives. Accessed: June 30, 2026. Available from: https://iris.who.int/bitstream/handle/10665/347370/9789240025271-eng.pdf

Ref. 68. International Agency for Research on Cancer. Cancer Tomorrow. Accessed: June 30, 2026. Available from: https://gco.iarc.who.int/today/

Ref. 69. Ward ZJ, et al. (2019) Lancet Oncol, 20: 483. Available from: https://doi.org/10.1016/S1470-2045(18)30909-4

Ref. 70. Daltveit DS, et al. (2025) JNCI: Journal of the National Cancer Institute. Available from: https://doi.org/10.1093/jnci/djaf321

Ref. 71. Mikkelsen MK, et al. (2026) JAMA Netw Open, 9: e2552510. Available from: https://doi.org/10.1001/jamanetworkopen.2025.52510

Ref. 72. Jefford M, et al. (2025) Lancet Reg Health West Pac, 65: 101748. Available from: https://doi.org/10.1016/j.lanwpc.2025.101748

Ref. 73. Barragan-Carrillo R, et al. (2025) American Society of Clinical Oncology Educational Book, 45: e473930. Available from: https://doi.org/10.1200/EDBK-25-473930

Ref. 74. Al Sukhun SA, et al. (2024) JCO Glob Oncol, 10: e2400015. Available from: https://doi.org/10.1200/GO.24.00015

Ref. 75. McIntosh SA, et al. (2023) Lancet Oncol, 24: 636. Available from: https://doi.org/10.1016/S1470-2045(23)00182-1

Ref. 76. Ngo P, et al. (2026) J Natl Cancer Inst Monogr, 2026: 3. Available from: https://doi.org/10.1093/jncimonographs/lgag005

Ref. 77. Mariotto AB, et al. (2020) Cancer Epidemiol Biomarkers Prev, 29: 1304. Available from: https://doi.org/10.1158/1055-9965.EPI-19-1534

Ref. 78. Kong YC, et al. (2025) J Natl Cancer Inst, 117: 2612. Available from: https://doi.org/10.1093/jnci/djaf193

Ref. 79. Parsons SK, et al. (2023) J Clin Oncol, 41: 3260. Available from: https://doi.org/10.1200/JCO.22.01985

Ref. 80. Yabroff KR, et al. (2021) J Natl Cancer Inst, 113: 1670. Available from: https://doi.org/10.1093/jnci/djab192

Ref. 81. Chen S, et al. (2023) JAMA Oncol, 9: 465. Available from: https://doi.org/10.1001/jamaoncol.2022.7826

Ref. 82. Mohindroo C, et al. (2026) JAMA Netw Open, 9: e267837. Available from: https://doi.org/10.1001/jamanetworkopen.2026.7837

Ref. 83. United For Medical Research. NIH’s Role in Sustaining the U.S. Economy: Creating Jobs and Strengthening Local Economies. Accessed: June 30, 2026. Available from: https://www.unitedformedicalresearch.org/wp-content/uploads/2026/03/UMR_2026-Annual-Economic-Report-FY2025.pdf

Ref. 84. Association of American Medical Colleges. Impact of NIH Grant Terminations. Accessed: June 30, 2026. Available from: https://www.aamc.org/about-us/mission-areas/biomedical-research/publication/impact-nih-grant-terminations

Ref. 85. Oliveira DFM, et al. (2026) Proc Natl Acad Sci U S A, 123: e2527755123. Available from: https://doi.org/10.1073/pnas.2527755123

Ref. 86. Patel VR, et al. (2026) JAMA Intern Med, 186: 126. Available from: https://doi.org/10.1001/jamainternmed.2025.6088

Ref. 87. US Department of Human and Health Services. Budget in Brief. Fiscal Year 2027. Accessed: June 30, 2026. Available from: https://www.hhs.gov/sites/default/files/fy-2027-budget-in-brief.pdf

Ref. 88. (2025) Nature, 640: S65. Available from: https://doi.org/10.1038/d41586-025-01154-4

Ref. 89. Kang SY, et al. (2026) JAMA, 335: 1355. Available from: https://doi.org/10.1001/jama.2026.1962

Ref. 90. Plackett B (2025) Nature, 640: S58. Available from: https://doi.org/10.1038/d41586-025-01152-6

Ref. 91. Hanahan D (2026) Cell, 189: 2254. Available from: https://doi.org/10.1016/j.cell.2025.12.049

Ref. 92. National Institutes of Health. The Office of Budget. National Institutes of Health FY 2003 – FY 2024 Distribution of Budget Authority Percentages for Basic and Applied Research. Accessed: June 30, 2026. Available from: https://officeofbudget.od.nih.gov/pdfs/FY26/spending_hist/Basic%20and%20Applied%20FY%202003%20-%20FY%202024.pdf

Ref. 93. National Institutes of Health. NIH invests $150 million in human-based research to reduce use of animal models. Accessed: June 30, 2026. Available from: https://www.nih.gov/news-events/news-releases/nih-invests-150-million-human-based-research-reduce-use-animal-models

Ref. 94. US Food and Drug Administration. FDA Issues Draft Guidance to Cut Unnecessary Animal Testing for Cancer Drugs. Accessed: June 30, 2026. Available from: https://www.fda.gov/news-events/press-announcements/fda-issues-draft-guidance-cut-unnecessary-animal-testing-cancer-drugs

Ref. 95. Harrison C (2025) Lab Anim (NY), 54: 250. Available from: https://doi.org/10.1038/s41684-025-01619-z

Ref. 96. Lloyd KCK (2025) Nature, 646: 802. Available from: https://doi.org/10.1038/d41586-025-03345-5

Ref. 97. Riedl JM, et al. (2026) Cancer Cell, 44: 471. Available from: https://doi.org/10.1016/j.ccell.2026.01.001

Ref. 98. O’Reilly EM, et al. (2026) N Engl J Med. Available from: https://doi.org/10.1056/NEJMoa2605555

Ref. 99. Choucair K, et al. (2025) Signal Transduct Target Ther, 10: 385. Available from: https://doi.org/10.1038/s41392-025-02473-8

Ref. 100. Park W, et al. (2026) N Engl J Med, 394: 1409. Available from: https://doi.org/10.1056/NEJMoa2600752

Ref. 101. Wainberg ZA, et al. (2025) Nat Med, 31: 3648. Available from: https://doi.org/10.1038/s41591-025-03876-4

Ref. 102. Benton A, et al. (2025) Cancer Cell, 43: 1365. Available from: https://doi.org/10.1016/j.ccell.2025.05.006

Ref. 103. Modest DP, et al. (2025) Lancet Oncol, 26: 1240. Available from: https://doi.org/10.1016/s1470-2045(25)00352-3

Ref. 104. Huff AL, et al. (2026) Nat Commun, 17: 1538. Available from: https://doi.org/10.1038/s41467-026-68324-4

Ref. 105. De Dominici M, et al. (2026) Cancer Discov, 16: 16. Available from: https://doi.org/10.1158/2159-8290.Cd-25-0779

Ref. 106. Chan JE, et al. (2026) Nature, 651: 231. Available from: https://doi.org/10.1038/s41586-025-09985-x

Ref. 107. Yashinskie JJ, et al. (2026) Nat Cell Biol, 28: 296. Available from: https://doi.org/10.1038/s41556-025-01853-0

Ref. 108. Chen Z, et al. (2025) Cancer Res, 85: 3930. Available from: https://doi.org/10.1158/0008-5472.Can-25-0523

Ref. 109. Verma A, et al. (2025) Exp Mol Med, 57: 1928. Available from: https://doi.org/10.1038/s12276-025-01537-7

Ref. 110. Idumah G, et al. (2025) Jama, 334: 1765. Available from: https://doi.org/10.1001/jama.2025.16372

Ref. 111. Collister JA, et al. (2025) NPJ Breast Cancer, 11: 111. Available from: https://doi.org/10.1038/s41523-025-00826-8

Ref. 112. Liu J, et al. (2025) Nat Genet, 57: 1872. Available from: https://doi.org/10.1038/s41588-025-02250-x

Ref. 113. Weinstock JS, et al. (2025) Nat Commun, 16: 9194. Available from: https://doi.org/10.1038/s41467-025-64236-x

Ref. 114. Agarwal G, et al. (2026) Science, 391: 52. Available from: https://doi.org/10.1126/science.adx4174

Ref. 115. Barnes DR, et al. (2025) NPJ Genom Med, 10: 73. Available from: https://doi.org/10.1038/s41525-025-00529-w

Ref. 116. Calvet F, et al. (2025) Nature, 647: 436. Available from: https://doi.org/10.1038/s41586-025-09521-x

Ref. 117. Lawson ARJ, et al. (2025) Nature, 647: 411. Available from: https://doi.org/10.1038/s41586-025-09584-w

Ref. 118. Braxton AM, et al. (2024) Nature, 629: 679. Available from: https://doi.org/10.1038/s41586-024-07359-3

Ref. 119. Li J, et al. (2025) Lancet Oncol, 26: 1055. Available from: https://doi.org/10.1016/s1470-2045(25)00239-6

Ref. 120. Pich O, et al. (2026) Nature, 653: 900. Available from: https://doi.org/10.1038/s41586-025-09792-4

Ref. 121. Wong IT, et al. (2026) Cell, 189: 2307. Available from: https://doi.org/10.1016/j.cell.2026.03.011

Ref. 122. Chowdhury B, et al. (2025) Nat Commun, 17: 894. Available from: https://doi.org/10.1038/s41467-025-67614-7

Ref. 123. Guan R, et al. (2026) Oncogene, 45: 1100. Available from: https://doi.org/10.1038/s41388-026-03713-z

Ref. 124. Montuori G, et al. (2025) Cancer Discov, 15: 2054. Available from: https://doi.org/10.1158/2159-8290.Cd-24-1738

Ref. 125. Krupina K, et al. (2025) Science, 390: 1156. Available from: https://doi.org/10.1126/science.ado0977

Ref. 126. Noorani I, et al. (2025) Cancer Discov, 15: 2078. Available from: https://doi.org/10.1158/2159-8290.Cd-24-1555

Ref. 127. Zhang J, et al. (2025) Clin Cancer Res, 31: 4529. Available from: https://doi.org/10.1158/1078-0432.CCR-24-3399

Ref. 128. Wong IT, et al. (2026) Nat Rev Drug Discov, 25: 374. Available from: https://doi.org/10.1038/s41573-025-01369-0

Ref. 129. Sankar V, et al. (2026) Nature, 649: 152. Available from: https://doi.org/10.1038/s41586-025-09764-8

Ref. 130. Taghbalout A, et al. (2025) Cancer Cell, 43: 2191. Available from: https://doi.org/10.1016/j.ccell.2025.08.008

Ref. 131. Kraft K, et al. (2025) Nat Cell Biol, 27: 1914. Available from: https://doi.org/10.1038/s41556-025-01788-6

Ref. 132. National Cancer Institute. Targeted Therapy Drug List by Cancer Type. Accessed: June 30, 2026. Available from: https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/approved-drug-list

Ref. 133. Pan T, et al. (2026) Cancer Res, 86: 146. Available from: https://doi.org/10.1158/0008-5472.CAN-25-0021

Ref. 134. Kral AJ, et al. (2026) Mol Cell, 86: 60. Available from: https://doi.org/10.1016/j.molcel.2025.12.004

Ref. 135. Wagner V, et al. (2026) Nat Commun, 17. Available from: https://doi.org/10.1038/s41467-026-71564-z

Ref. 136. Hashemi M, et al. (2025) Cancer Cell Int, 25: 350. Available from: https://doi.org/10.1186/s12935-025-03999-1

Ref. 137. Bitaraf A, et al. (2025) Mol Cancer, 24: 245. Available from: https://doi.org/10.1186/s12943-025-02415-6

Ref. 138. Xue Z, et al. (2026) Mol Cancer Res, 24: 283. Available from: https://doi.org/10.1158/1541-7786.MCR-25-0321

Ref. 139. Díaz-Gay M, et al. (2025) Nature, 644: 133. Available from: https://doi.org/10.1038/s41586-025-09219-0

Ref. 140. Zhao W, et al. (2026) Cancer Discov, 16: 460. Available from: https://doi.org/10.1158/2159-8290.CD-25-0581

Ref. 141. Siddaway R, et al. (2025) Nat Med, 31: 3524. Available from: https://doi.org/10.1038/s41591-025-03848-8

Ref. 142. Knol JC, et al. (2025) Cancer Cell, 43: 1328. Available from: https://doi.org/10.1016/j.ccell.2025.05.003

Ref. 143. Bernardi F, et al. (2026) Cancer Cell, 44: 383. Available from: https://doi.org/10.1016/j.ccell.2025.12.012

Ref. 144. Wen B, et al. (2025) Nat Methods, 22: 1857. Available from: https://doi.org/10.1038/s41592-025-02797-x

Ref. 145. Ivanisevic T, et al. (2025) Nat Commun, 17: 411. Available from: https://doi.org/10.1038/s41467-025-67109-5

Ref. 146. International Agency for Research on Cancer. Central Nervous System Tumours. WHO Classification of Tumours, 5th Edition, Volume 6. Accessed: June 30, 2026. Available from: https://publications.iarc.who.int/601

Ref. 147. Sill M, et al. (2026) Cancer Cell, 44: 340. Available from: https://doi.org/10.1016/j.ccell.2025.11.002

Ref. 148. Steinicke TL, et al. (2025) Nat Genet, 57: 2456. Available from: https://doi.org/10.1038/s41588-025-02321-z

Ref. 149. Calabrò L, et al. (2026) Nat Genet, 58: 1100. Available from: https://doi.org/10.1038/s41588-026-02580-4

Ref. 150. Jung SY, et al. (2025) Aging (Albany NY), 17: 1624. Available from: https://doi.org/10.18632/aging.206276

Ref. 151. Nagaraja S, et al. (2026) Nature, 652: 774. Available from: https://doi.org/10.1038/s41586-026-10258-4

Ref. 152. Jin N, et al. (2025) Cancer Res Commun, 5: 1985. Available from: https://doi.org/10.1158/2767-9764.Crc-25-0177

Ref. 153. Subudhi S, et al. (2026) Cell, 189: 2379. Available from: https://doi.org/10.1016/j.cell.2026.03.016

Ref. 154. Kabir AU, et al. (2026) Nat Rev Immunol, 26: 35. Available from: https://doi.org/10.1038/s41577-025-01211-z

Ref. 155. Nahar S, et al. (2026) Mol Cancer Res, 24: 258. Available from: https://doi.org/10.1158/1541-7786.MCR-25-0544

Ref. 156. Haist M, et al. (2026) Cancer Cell, 44: 604. Available from: https://doi.org/10.1016/j.ccell.2026.01.003

Ref. 157. Eichin D, et al. (2025) Nat Commun, 16: 10056. Available from: https://doi.org/10.1038/s41467-025-64981-z

Ref. 158. Tufail M, et al. (2025) Signal Transduct Target Ther, 10: 227. Available from: https://doi.org/10.1038/s41392-025-02280-1

Ref. 159. Li D, et al. (2026) Nat Cell Biol, 28: 349. Available from: https://doi.org/10.1038/s41556-025-01839-y

Ref. 160. Terasaki A, et al. (2026) Cell Metab, 38: 388. Available from: https://doi.org/10.1016/j.cmet.2025.12.014

Ref. 161. Sun R, et al. (2026) Nature Metabolism, 8: 196. Available from: https://doi.org/10.1038/s42255-025-01430-7

Ref. 162. Li B, et al. (2025) Cell, 188: 3823. Available from: https://doi.org/10.1016/j.cell.2025.04.032

Ref. 163. Monje M, et al. (2025) Nat Cancer, 6: 1928. Available from: https://doi.org/10.1038/s43018-025-01082-2

Ref. 164. Chen MM, et al. (2025) Cancer Cell, 43: 1656. Available from: https://doi.org/10.1016/j.ccell.2025.06.020

Ref. 165. Savchuk S, et al. (2025) Nature, 646: 1232. Available from: https://doi.org/10.1038/s41586-025-09492-z

Ref. 166. Sakthivelu V, et al. (2025) Nature, 646: 1243. Available from: https://doi.org/10.1038/s41586-025-09434-9

Ref. 167. Wei HK, et al. (2026) Nature, 650: 1007. Available from: https://doi.org/10.1038/s41586-025-10028-8

Ref. 168. Liao F, et al. (2026) Cancer Res, 86: 1968. Available from: https://doi.org/10.1158/0008-5472.CAN-25-3092

Ref. 169. Baruch EN, et al. (2025) Nature, 646: 462. Available from: https://doi.org/10.1038/s41586-025-09370-8

Ref. 170. Yao Y, et al. (2026) Signal Transduct Target Ther, 11: 39. Available from: https://doi.org/10.1038/s41392-025-02335-3

Ref. 171. Nobels A, et al. (2025) Nat Metab, 7: 895. Available from: https://doi.org/10.1038/s42255-025-01287-w

Ref. 172. Bautista J, et al. (2026) NPJ Biofilms Microbiomes, 12: 21. Available from: https://doi.org/10.1038/s41522-025-00883-8

Ref. 173. Díaz-Gay M, et al. (2025) Nature, 643: 230. Available from: https://doi.org/10.1038/s41586-025-09025-8

Ref. 174. Carlson ES, et al. (2025) Science, 390: eady3571. Available from: https://doi.org/10.1126/science.ady3571

Ref. 175. Osswald A, et al. (2025) Gut. Available from: https://doi.org/10.1136/gutjnl-2024-332243

Ref. 176. Qiao S, et al. (2026) Cell Host Microbe, 34: 18. Available from: https://doi.org/10.1016/j.chom.2025.12.003

Ref. 177. Shi Z, et al. (2025) Nat Commun, 17: 346. Available from: https://doi.org/10.1038/s41467-025-67047-2

Ref. 178. Yang Y, et al. (2025) Cell Rep Med, 6: 102234. Available from: https://doi.org/10.1016/j.xcrm.2025.102234

Ref. 179. Petersen AE, et al. (2026) JCO Oncol Adv, 3. Available from: https://doi.org/10.1200/oa-25-00042

Ref. 180. Martinez-Martinez D, et al. (2025) Cell Syst, 16: 101397. Available from: https://doi.org/10.1016/j.cels.2025.101397

Ref. 181. Chen J, et al. (2025) Nat Rev Clin Oncol, 22: 667. Available from: https://doi.org/10.1038/s41571-025-01052-8

Ref. 182. He J, et al. (2025) Mol Med, 31: 58. Available from: https://doi.org/10.1186/s10020-025-01108-6

Ref. 183. Xie M, et al. (2025) Cell Mol Immunol, 22: 1012. Available from: https://doi.org/10.1038/s41423-025-01326-2

Ref. 184. Porcari S, et al. (2026) Nat Med, 32: 1316. Available from: https://doi.org/10.1038/s41591-025-04189-2

Ref. 185. Fernandes R, et al. (2026) Nat Med, 32: 1325. Available from: https://doi.org/10.1038/s41591-025-04183-8

Ref. 186. Duttagupta S, et al. (2026) Nat Med, 32: 1337. Available from: https://doi.org/10.1038/s41591-025-04186-5

Ref. 187. Marcos-Kovandzic L, et al. (2025) Cancer Discov, 15: 1905. Available from: https://doi.org/10.1158/2159-8290.Cd-24-1230

Ref. 188. Parida S, et al. (2026) Cell Commun Signal, 24. Available from: https://doi.org/10.1186/s12964-025-02635-9

Ref. 189. Hajjar R, et al. (2026) Nat Rev Microbiol, 24: 392. Available from: https://doi.org/10.1038/s41579-025-01268-6

Ref. 190. Li YR, et al. (2025) Cancer Discov, 15: 1115. Available from: https://doi.org/10.1158/2159-8290.CD-24-1379

Ref. 191. Zhao W, et al. (2025) Nat Cancer, 6: 1857. Available from: https://doi.org/10.1038/s43018-025-01053-7

Ref. 192. Xing X, et al. (2025) Cancer Cell, 43: 1242. Available from: https://doi.org/10.1016/j.ccell.2025.03.025

Ref. 193. Tzouanas CN, et al. (2026) Cell, 189: 435. Available from: https://doi.org/10.1016/j.cell.2025.11.031

Ref. 194. Feng T, et al. (2025) Nat Metab, 7: 2018. Available from: https://doi.org/10.1038/s42255-025-01368-w

Ref. 195. Cheng C, et al. (2025) Nature, 642: 776. Available from: https://doi.org/10.1038/s41586-025-08917-z

Ref. 196. Scott AJ, et al. (2025) Nature, 646: 413. Available from: https://doi.org/10.1038/s41586-025-09460-7

Ref. 197. Wu K, et al. (2026) Nature, 649: 487. Available from: https://doi.org/10.1038/s41586-025-09710-8

Ref. 198. Palma M, et al. (2026) Nature, 649: 477. Available from: https://doi.org/10.1038/s41586-025-09709-1

Ref. 199. Patel AAH, et al. (2026) Nature, 652: 1339. Available from: https://doi.org/10.1038/s41586-026-10216-0

Ref. 200. Shuldiner EG, et al. (2025) Nat Aging, 5: 2263. Available from: https://doi.org/10.1038/s43587-025-00986-z

Ref. 201. Zhuang X, et al. (2025) Nature, 637: 184. Available from: https://doi.org/10.1038/s41586-024-08285-0

Ref. 202. Pich O, et al. (2025) N Engl J Med, 392: 1594. Available from: https://doi.org/10.1056/NEJMoa2413361

Ref. 203. Yang H, et al. (2025) Mol Cancer, 24: 237. Available from: https://doi.org/10.1186/s12943-025-02459-8

Ref. 204. van Putten J, et al. (2026) Nat Med, 32: 1286. Available from: https://doi.org/10.1038/s41591-026-04280-2

Ref. 205. Kim R, et al. (2026) Nature, 649: 1282. Available from: https://doi.org/10.1038/s41586-025-09812-3

Ref. 206. Till A, et al. (2025) Nat Med, 31: 3981. Available from: https://doi.org/10.1038/s41591-025-03991-2

Ref. 207. Aavikko M, et al. (2026) Nat Rev Cancer, 26: 159. Available from: https://doi.org/10.1038/s41568-025-00885-w

Ref. 208. Yang HC, et al. (2025) Nature, 648: 117. Available from: https://doi.org/10.1038/s41586-025-09680-x

Ref. 209. Liu F, et al. (2026) Nat Rev Cancer, 26: 497. Available from: https://doi.org/10.1038/s41568-026-00922-2

Ref. 210. Goodwin RJA, et al. (2026) Cancer Discov, 16: 847. Available from: https://doi.org/10.1158/2159-8290.Cd-26-0271

Ref. 211. The White House. Unlocking Cures for Pediatric Cancer with Artificial Intelligence. Accessed: June 30, 2026. Available from: https://www.whitehouse.gov/presidential-actions/2025/09/unlocking-cures-for-pediatric-cancer-with-artificial-intelligence/

Ref. 212. Avsec Ž, et al. (2026) Nature, 649: 1206. Available from: https://doi.org/10.1038/s41586-025-10014-0

Ref. 213. Broad Institute. Cancer Dependency Map Consortium launches Phase 3 to accelerate next-generation therapeutics. Accessed: June 30, 2026. Available from: https://www.broadinstitute.org/news/cancer-dependency-map-consortium-launches-phase-3-accelerate-next-generation-therapeutics

Ref. 214. Enninful A, et al. (2026) Nat Methods. Available from: https://doi.org/10.1038/s41592-025-02948-0

Ref. 215. Jiménez-Sánchez A, et al. (2026) Cancer Res, 86: 1769. Available from: https://doi.org/10.1158/0008-5472.Can-25-1117

Ref. 216. Tandukar B, et al. (2026) Nat Cell Biol, 28: 1300. Available from: https://doi.org/10.1038/s41556-026-01943-7

Ref. 217. Tandukar B, et al. (2025) Nat Commun, 16: 10663. Available from: https://doi.org/10.1038/s41467-025-65687-y

Ref. 218. National Cancer Institute. NCI Human Tumor Atlas Network. Accessed: June 30, 2026. Available from: https://humantumoratlas.org/

Ref. 219. Eccles RL, et al. (2026) Cancer Discov, 16: 633. Available from: https://doi.org/10.1158/2159-8290.Cd-26-0215

Ref. 220. Liu Y, et al. (2026) Cancer Discov, 16: 660. Available from: https://doi.org/10.1158/2159-8290.Cd-25-2051

Ref. 221. Islami F, et al. (2024) CA Cancer J Clin, 74: 405. Available from: https://doi.org/10.3322/caac.21858

Ref. 222. Force LM, et al. (2025) The Lancet, 406: 1565. Available from: https://doi.org/10.1016/S0140-6736(25)01635-6

Ref. 223. American Association for Cancer Research. AACR Cancer Progress Report 2023. Accessed: June 30, 2026. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2023/10/AACR_CPR_2023_102423.pdf

Ref. 224. Goddard KAB, et al. (2025) JAMA Oncol, 11: 162. Available from: https://doi.org/10.1001/jamaoncol.2024.5381

Ref. 225. National Institute on Alcohol Abuse and Alcoholism. Alcohol Use in the United States: Age Groups and Demographic Characteristics. Accessed: June 30, 2026. Available from: https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-topics/alcohol-facts-and-statistics

Ref. 226. Larios D, et al. (2025) The Journal of Climate Change and Health, 25: 100573. Available from: https://doi.org/10.1016/j.joclim.2025.100573

Ref. 227. Hiatt RA, et al. (2026) American Society of Clinical Oncology Educational Book, 46: e521654. Available from: https://doi.org/10.1200/EDBK-26-521654

Ref. 228. Kriit HK, et al. (2026) The Lancet Public Health, 11: e386. Available from: https://doi.org/10.1016/S2468-2667(26)00025-3

Ref. 229. Li S, et al. (2025) J Expo Sci Environ Epidemiol, 35: 425. Available from: https://doi.org/10.1038/s41370-024-00742-2

Ref. 230. Demers PA, et al. (2022) The Lancet Oncology, 23: 985. Available from: https://doi.org/10.1016/S1470-2045(22)00390-4

Ref. 231. Dai H, et al. (2025) JAMA Oncology, 11: 1186. Available from: https://doi.org/10.1001/jamaoncol.2025.2681

Ref. 232. White AJ, et al. (2021) Carcinogenesis, 42: 1189. Available from: https://doi.org/10.1093/carcin/bgab056

Ref. 233. Chang CJ, et al. (2022) J Natl Cancer Inst, 114: 1636. Available from: https://doi.org/10.1093/jnci/djac165

Ref. 234. NBC News. Congress targets hair products with cancer-causing ingredients marketed to Black women. Accessed: June 30, 2026. Available from: https://www.nbcnews.com/news/nbcblk/congress-targets-hair-products-cancer-causing-ingredients-marketed-bla-rcna219350

Ref. 235. Polineni V, et al. (2026) Journal of Clinical Oncology, 44: 11014. Available from: https://doi.org/10.1200/JCO.2026.44.16_suppl.11014

Ref. 236. IARC Working Group on the Identification of Carcinogenic Hazards to Humans. Night Shift Work. Accessed: June 30, 2026. Available from: https://www.ncbi.nlm.nih.gov/books/NBK568199/

Ref. 237. Barber LE, et al. (2024) Cancer Epidemiol Biomarkers Prev, 33: 471. Available from: https://doi.org/10.1158/1055-9965.Epi-23-1117

Ref. 238. Beane Freeman LE, et al. (2022) Environ Health Perspect, 130: 57006. Available from: https://doi.org/10.1289/EHP9895

Ref. 239. Purdue MP, et al. (2023) Environ Health Perspect, 131: 77007. Available from: https://doi.org/10.1289/EHP12603

Ref. 240. Alexandrov LB, et al. (2016) Science, 354: 618. Available from: https://doi.org/10.1126/science.aag0299

Ref. 241. Pezzuto A, et al. (2019) Future Sci OA, 5: FSO394. Available from: https://doi.org/10.2144/fsoa-2019-0017

Ref. 242. Yang Y, et al. (2023) J Hazard Mater, 455: 131556. Available from: https://doi.org/10.1016/j.jhazmat.2023.131556

Ref. 243. American Cancer Society. US Tobacco Atlas. Accessed: June 30, 2026. Available from: https://ustobaccoatlas.cancer.org/

Ref. 244. US Department of Health and Human Services. Office of Disease Prevention and Health Promotion. Reduce current cigarette smoking in adults — TU‑02 – Healthy People 2030. Accessed: June 30, 2026. Available from: https://odphp.health.gov/healthypeople/objectives-and-data/browse-objectives/tobacco-use/reduce-current-cigarette-smoking-adults-tu-02

Ref. 245. Arrazola RA, et al. (2025) MMWR Morb Mortal Wkly Rep, 74: 118. Available from: https://doi.org/10.15585/mmwr.mm7407a3

Ref. 246. American Lung Association. State of Tobacco Control. Accessed: June 30, 2026. Available from: https://www.lung.org/research/sotc

Ref. 247. Jamal A, et al. (2024) MMWR Morb Mortal Wkly Rep, 73: 917. Available from: https://doi.org/10.15585/mmwr.mm7341a2

Ref. 248. Park-Lee E, et al. (2026) Nicotine & Tobacco Research. Available from: https://doi.org/10.1093/ntr/ntag116

Ref. 249. Bandi P, et al. (2025) Tob Control. Available from: https://doi.org/10.1136/tc-2024-059020

Ref. 250. Bandi P, et al. (2026) Tob Control, 35: 366. Available from: https://doi.org/10.1136/tc-2024-059020

Ref. 251. Delnevo CD, et al. (2011) Am J Prev Med, 41: 357. Available from: https://doi.org/10.1016/j.amepre.2011.06.039

Ref. 252. Centers for Disease Control and Prevention. Menthol Tobacco Products. Accessed: June 30, 2026. Available from: https://www.cdc.gov/tobacco/menthol-tobacco/index.html

Ref. 253. Blewett LA, et al. IPUMS Health Surveys: National Health Interview Survey. 8.1 ed. Minneapolis, MN: IPUMS; 2025

Ref. 254. Issabakhsh M, et al. (2023) Tob Control, 33: 126. Available from: https://doi.org/10.1136/tobaccocontrol-2022-057298

Ref. 255. Ganz O, et al. (2025) American Journal of Public Health, 115: 1206. Available from: https://doi.org/10.2105/ajph.2025.308116

Ref. 256. VanFrank B, et al. (2024) MMWR Morb Mortal Wkly Rep, 73: 633. Available from: https://doi.org/10.15585/mmwr.mm7329a1

Ref. 257. Le TTT, et al. (2024) Am J Prev Med, 67: 684. Available from: https://doi.org/10.1016/j.amepre.2024.06.020

Ref. 258. Stepanek L, et al. (2022) Int J Environ Res Public Health, 19. Available from: https://doi.org/10.3390/ijerph192013152

Ref. 259. Brody DJ, et al. (2021) National Health and Nutrition Examination Survey

Ref. 260. Seaman Jones EL, et al. (2026) Preventive Medicine Reports: 103536. Available from: https://doi.org/10.1016/j.pmedr.2026.103536

Ref. 261. Appolon G, et al. (2026) JAMA Health Forum, 7: e260631. Available from: https://doi.org/10.1001/jamahealthforum.2026.0631

Ref. 262. Goniewicz ML, et al. (2018) JAMA Netw Open, 1: e185937. Available from: https://doi.org/10.1001/jamanetworkopen.2018.5937

Ref. 263. Herbst RS, et al. (2022) Clin Cancer Res, 28: 4861. Available from: https://doi.org/10.1158/1078-0432.CCR-22-2429

Ref. 264. Sahu R, et al. (2023) Adv Respir Med, 91: 516. Available from: https://doi.org/10.3390/arm91060038

Ref. 265. Stewart BW, et al. (2026) Carcinogenesis, 47. Available from: https://doi.org/10.1093/carcin/bgag015

Ref. 266. Bittoni MA, et al. (2024) J Oncol Res Ther, 9. Available from: https://doi.org/10.29011/2574-710x.10229

Ref. 267. Kim YW, et al. (2026) Nature Medicine. Available from: https://doi.org/10.1038/s41591-026-04469-5

Ref. 268. Ng M, et al. (2025) The Lancet, 405: 813. Available from: https://doi.org/10.1016/S0140-6736(25)00355-1

Ref. 269. Percentage of obesity for adults aged 18 and over, United States, 2019—2024. Accessed: June 30, 2026. Available from: https://wwwn.cdc.gov/NHISDataQueryTool/SHS_adult/index.html

Ref. 270. Piercy KL, et al. (2018) JAMA, 320: 2020. Available from: https://doi.org/10.1001/jama.2018.14854

Ref. 271. Matthews CE, et al. (2020) J Clin Oncol, 38: 686. Available from: https://doi.org/10.1200/JCO.19.02407

Ref. 272. Patel AV, et al. (2019) Med Sci Sports Exerc, 51: 2391. Available from: https://doi.org/10.1249/MSS.0000000000002117

Ref. 273. Moore SC, et al. (2016) JAMA Intern Med, 176: 816. Available from: https://doi.org/10.1001/jamainternmed.2016.1548

Ref. 274. Clinton SK, et al. (2020) J Nutr, 150: 663. Available from: https://doi.org/10.1093/jn/nxz268

Ref. 275. Lauby-Secretan B, et al. (2016) N Engl J Med, 375: 794. Available from: https://doi.org/10.1056/NEJMsr1606602

Ref. 276. Degenhardt L, et al. (2018) The Lancet Psychiatry, 5: 987. Available from: https://doi.org/10.1016/S2215-0366(18)30337-7

Ref. 277. Heerman WJ, et al. (2026) JAMA Network Open, 9: e2558710. Available from: https://doi.org/10.1001/jamanetworkopen.2025.58710

Ref. 278. Mohammadian Khonsari N, et al. (2023) Front Endocrinol (Lausanne), 14: 1069164. Available from: https://doi.org/10.3389/fendo.2023.1069164

Ref. 279. Pénisson S, et al. (2026) Cancer Research, 86: 2678. Available from: https://doi.org/10.1158/0008-5472.Can-25-2487

Ref. 280. Brauer M, et al. (2024) The Lancet, 403: 2162. Available from: https://doi.org/10.1016/S0140-6736(24)00933-4

Ref. 281. London. World Obesity Atlas 2025. Accessed: June 30, 2026. Available from: https://data.worldobesity.org/publications/?cat=23

Ref. 282. Rubino F, et al. (2025) Lancet Diabetes Endocrinol, 13: 221. Available from: https://doi.org/10.1016/S2213-8587(24)00316-4

Ref. 283. Wagner DR, et al. (2000) Am J Clin Nutr, 71: 1392. Available from: https://doi.org/10.1093/ajcn/71.6.1392

Ref. 284. Winter JE, et al. (2014) Am J Clin Nutr, 99: 875. Available from: https://doi.org/10.3945/ajcn.113.068122

Ref. 285. Zamboni M, et al. (2008) Nutr Metab Cardiovasc Dis, 18: 388. Available from: https://doi.org/10.1016/j.numecd.2007.10.002

Ref. 286. WHO Expert Consultation (2004) Lancet, 363: 157. Available from: https://doi.org/10.1016/S0140-6736(03)15268-3

Ref. 287. Celletti F, et al. (2026) Lancet Glob Health, 14: e653. Available from: https://doi.org/10.1016/s2214-109x(25)00496-6

Ref. 288. Shams-White MM, et al. (2022) Curr Dev Nutr, 6: nzac096. Available from: https://doi.org/10.1093/cdn/nzac096

Ref. 289. American Association for Cancer Research. AACR Cancer Disparities Progress Report 2022. Accessed: June 30, 2026. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2022/06/AACR_CDPR_2022.pdf

Ref. 290. Ipaye T, et al. (2025) Diabetes, Obesity and Metabolism, 27: 6914. Available from: https://doi.org/10.1111/dom.70090

Ref. 291. Wilson RB, et al. (2023) Int J Mol Sci, 24. Available from: https://doi.org/10.3390/ijms24076192

Ref. 292. Bettadapura S, et al. (2025) Int J Obes (Lond), 49: 418. Available from: https://doi.org/10.1038/s41366-024-01500-y

Ref. 293. McDonald ES, et al. (2026) JCO Oncology Practice, 0: OP. Available from: https://doi.org/10.1200/OP-26-00485

Ref. 294. Temperley HC, et al. (2026) Journal of Clinical Oncology, 0: JCO. Available from: https://doi.org/10.1200/JCO-26-00062

Ref. 295. Wolff Sagy Y, et al. (2025) EClinicalMedicine, 83: 103213. Available from: https://doi.org/10.1016/j.eclinm.2025.103213

Ref. 296. Wang L, et al. (2024) JAMA Netw Open, 7: e2421305. Available from: https://doi.org/10.1001/jamanetworkopen.2024.21305

Ref. 297. Levy S, et al. (2024) Cancers, 17: 78. Available from: https://doi.org/10.3390/cancers17010078

Ref. 298. Ko A, et al. (2026) Ann Intern Med, 179: 216. Available from: https://doi.org/10.7326/ANNALS-25-02237

Ref. 299. Mechanick JI, et al. (2019) Endocr Pract, 25: 1346. Available from: https://doi.org/10.4158/GL-2019-0406

Ref. 300. Collins L, et al. Glucagon-Like Peptide-1 Receptor Agonists. StatPearls. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551568/

Ref. 301. Ryan D, et al. (2014) Obesity (Silver Spring), 22 Suppl 2: S1. Available from: https://doi.org/10.1002/oby.20819

Ref. 302. Santos B, et al. (2026) Res Sq. Available from: https://doi.org/10.21203/rs.3.rs-8380296/v1

Ref. 303. Pant S (2025) JAMA, 334: 1506. Available from: https://doi.org/10.1001/jama.2025.17483

Ref. 304. Barrett TS, et al. (2025) JAMA Surgery, 160: 1232. Available from: https://doi.org/10.1001/jamasurg.2025.3590

Ref. 305. Donaldson MS (2004) Nutr J, 3: 19. Available from: https://doi.org/10.1186/1475-2891-3-19

Ref. 306. US Department of Agriculture. Dietary Guidelines for Americans, 2025-2030. Accessed: June 30, 2026. Available from: https://cdn.realfood.gov/DGA.pdf

Ref. 307. Dunneram Y, et al. (2026) British Journal of Cancer, 134: 1218. Available from: https://doi.org/10.1038/s41416-025-03327-4

Ref. 308. Fraser GE, et al. (2025) Am J Clin Nutr, 122: 535. Available from: https://doi.org/10.1016/j.ajcnut.2025.06.006

Ref. 309. Monteiro CA, et al. (2019) Public Health Nutr, 22: 936. Available from: https://doi.org/10.1017/S1368980018003762

Ref. 310. Wang K, et al. (2025) Thorax, 80: 810. Available from: https://doi.org/10.1136/thorax-2024-222100

Ref. 311. Lai B, et al. (2025) BMC Gastroenterology, 25: 575. Available from: https://doi.org/10.1186/s12876-025-04163-9

Ref. 312. Wiese D, et al. (2026) American Journal of Public Health, 116: 1004. Available from: https://doi.org/10.2105/ajph.2026.308495

Ref. 313. Lopez-Bueno R, et al. (2023) JAMA Intern Med, 183: 982. Available from: https://doi.org/10.1001/jamainternmed.2023.3093

Ref. 314. Minihan AK, et al. (2022) Med Sci Sports Exerc, 54: 417. Available from: https://doi.org/10.1249/MSS.0000000000002801

Ref. 315. Strain T, et al. (2024) Lancet Glob Health, 12: e1232. Available from: https://doi.org/10.1016/s2214-109x(24)00150-5

Ref. 316. Salvo D, et al. (2026) Nature Medicine, 32: 1479. Available from: https://doi.org/10.1038/s41591-026-04237-5

Ref. 317. Zhang Y, et al. (2025) JAMA Oncology, 11: 1488. Available from: https://doi.org/10.1001/jamaoncol.2025.4185

Ref. 318. George S, et al. (2026) Journal of Studies on Alcohol and Drugs, 87: 621. Available from: https://doi.org/10.15288/jsad.25-00435

Ref. 319. Abraham I, et al. (2025) Cancer Epidemiology, 99: 102956. Available from: https://doi.org/10.1016/j.canep.2025.102956

Ref. 320. Dai X, et al. (2026) Nature Health. Available from: https://doi.org/10.1038/s44360-026-00139-5

Ref. 321. Havlikova J, et al. (2025) Communications Biology, 8: 1374. Available from: https://doi.org/10.1038/s42003-025-08769-3

Ref. 322. O’Connell CP, et al. (2026) Cancer, 132: e70201. Available from: https://doi.org/10.1002/cncr.70201

Ref. 323. Streck JM, et al. (2026) JAMA, 335: 93. Available from: https://doi.org/10.1001/jama.2025.19210

Ref. 324. Bandi P, et al. (2025) Cancer Epidemiol Biomarkers Prev, 34: 836. Available from: https://doi.org/10.1158/1055-9965.EPI-24-1835

Ref. 325. Ma K, et al. (2017) Med Sci Monit, 23: 238. Available from: https://doi.org/10.12659/msm.899423

Ref. 326. Zhao J, et al. (2026) International Journal of Alcohol and Drug Research. Available from: https://doi.org/10.7895/ijadr.649

Ref. 327. National Institute on Alcohol Abuse and Alcoholism. Alcohol Use in the United States: Age Groups and Demographic Characteristics. Accessed: June 30, 2026. Available from: https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-topics-z/alcohol-facts-and-statistics/alcohol-use-united-states-age-groups-and-demographic-characteristics

Ref. 328. Sánchez-Bayona R, et al. (2020) Nutrients, 12: 731. Available from: https://doi.org/10.3390/nu12030731

Ref. 329. Greene NK, et al. (2025) Cancer Epidemiology, Biomarkers & Prevention, 34: 2095. Available from: https://doi.org/10.1158/1055-9965.Epi-25-0243

Ref. 330. Delam H, et al. (2025) Annals of Pancreatic Cancer, 8. Available from: https://doi.org/10.21037/apc-24-31

Ref. 331. Naudin S, et al. (2025) PLoS Med, 22: e1004590. Available from: https://doi.org/10.1371/journal.pmed.1004590

Ref. 332. Jun S, et al. (2023) Epidemiol Health, 45: e2023092. Available from: https://doi.org/10.4178/epih.e2023092

Ref. 333. Annenberg Public Policy Center. University of Pennsylvania. Awareness of Alcohol-Cancer Link Holds Steady Despite Omission in New U.S. Dietary Guidelines. Accessed: June 30, 2026. Available from: https://www.annenbergpublicpolicycenter.org/awareness-of-alcohol-cancer-link-holds-steady-despite-omission-in-new-u-s-dietary-guidelines/

Ref. 334. Hay JL, et al. (2026) Cancer Epidemiology, Biomarkers & Prevention, 35: 389. Available from: https://doi.org/10.1158/1055-9965.Epi-25-1206

Ref. 335. Seidenberg AB, et al. (2023) Cancer Epidemiology, Biomarkers & Prevention, 32: 46. Available from: https://doi.org/10.1158/1055-9965.Epi-22-0420

Ref. 336. Grummon AH, et al. (2026) Journal of Studies on Alcohol and Drugs, 87: 433. Available from: https://doi.org/10.15288/jsad.25-00226

Ref. 337. Phillips JA (2021) Workplace Health Saf, 69: 395. Available from: https://doi.org/10.1177/21650799211026980

Ref. 338. Samarasekera U (2026) The Lancet Oncology, 27: 154. Available from: https://doi.org/10.1016/S1470-2045(26)00011-2

Ref. 339. Hosseinpour Z, et al. (2026) J Racial Ethn Health Disparities, 13: 2067. Available from: https://doi.org/10.1007/s40615-025-02399-5

Ref. 340. Bowers JM, et al. (2020) Am J Public Health, 110: 823. Available from: https://doi.org/10.2105/ajph.2020.305605

Ref. 341. Gerami P, et al. (2025) Science Advances, 11: eady4878. Available from: https://doi.org/10.1126/sciadv.ady4878

Ref. 342. The American Journal of Managed Care. 5 Questions Dermatology Patients May Have About Newly-Approved Bemotrizinol. Accessed: June 30, 2026. Available from: https://www.ajmc.com/view/5-questions-dermatology-patients-may-have-about-newly-approved-bemotrizinol

Ref. 343. Fink H, et al. (2026) Nature Medicine, 32: 1306. Available from: https://doi.org/10.1038/s41591-026-04219-7

Ref. 344. Cai H, et al. (2025) Front Oncol, 15: 1737423. Available from: https://doi.org/10.3389/fonc.2025.1737423

Ref. 345. Bray F, et al. (2024) CA Cancer J Clin, 74: 229. Available from: https://doi.org/10.3322/caac.21834

Ref. 346. World Cancer Report: Cancer research for cancer prevention. In: Wild CP, Weiderpass E, Stewart BW, editors. World Cancer Report: Cancer research for cancer prevention. Lyon (FR)2020

Ref. 347. American Cancer Society. Global Cancer Facts and Figures 5th Edition. Accessed: June 30, 2026. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf

Ref. 348. Chang Sing Pang KJW, et al. (2020) Cancers (Basel), 13. Available from: https://doi.org/10.3390/cancers13010045

Ref. 349. Munoz N, et al. (2003) N Engl J Med, 348: 518. Available from: https://doi.org/10.1056/NEJMoa021641

Ref. 350. Meng X, et al. (2025) Pathogens, 14. Available from: https://doi.org/10.3390/pathogens14090880

Ref. 351. Sasieni P, et al. The Lancet. Available from: https://doi.org/10.1016/S0140-6736(26)00918-9

Ref. 352. Pedersen K, et al. (2026) Ann Intern Med, 179: 497. Available from: https://doi.org/10.7326/annals-25-03192

Ref. 353. Pingali C, et al. (2025) MMWR Morb Mortal Wkly Rep, 74: 466. Available from: https://doi.org/10.15585/mmwr.mm7430a1

Ref. 354. Kreimer AR, et al. (2025) New England Journal of Medicine, 393: 2421. Available from: https://doi.org/doi:10.1056/NEJMoa2506765

Ref. 355. Centers for Disease Control and Prevention. 2025 Viral Hepatitis National Progress Report. Accessed: June 30, 2026. Available from: https://www.cdc.gov/hepatitis/php/npr-2025/index.html

Ref. 356. GlaxoSmithKilne. Bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B Accessed: June 30, 2026. Available from: https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-achieves-unprecedented-functional-cure-rates-with-potential-to-redefine-treatment-for-chronic-hepatitis-b/

Ref. 357. Hou J, et al. (2026) New England Journal of Medicine, 394: 2395. Available from: https://doi.org/doi:10.1056/NEJMoa2515131

Ref. 358. Casey O, et al. (2026) Front Gastroenterol (Lausanne), 5: 1740221. Available from: https://doi.org/10.3389/fgstr.2026.1740221

Ref. 359. Kumar S, et al. (2020) Gastroenterology, 158: 527. Available from: https://doi.org/10.1053/j.gastro.2019.10.019

Ref. 360. Han X, et al. (2026) Gut: gutjnl. Available from: https://doi.org/10.1136/gutjnl-2026-338156

Ref. 361. Lee Y-C, et al. (2026) JAMA. Available from: https://doi.org/10.1001/jama.2026.6908

Ref. 362. Hill W, et al. (2023) Nature, 616: 159. Available from: https://doi.org/10.1038/s41586-023-05874-3

Ref. 363. Luo G, et al. (2025) Lancet Respir Med, 13: 348. Available from: https://doi.org/10.1016/S2213-2600(24)00428-4

Ref. 364. Zhang Y, et al. (2025) BMC Public Health, 25: 1260. Available from: https://doi.org/10.1186/s12889-025-22450-8

Ref. 365. Wu AH, et al. (2025) J Clin Oncol, 43: 273. Available from: https://doi.org/10.1200/JCO.24.00418

Ref. 366. White AJ, et al. (2025) American Journal of Public Health, 115: 2030. Available from: https://doi.org/10.2105/ajph.2025.308247

Ref. 367. Williamson MR, et al. (2026) JAMA Network Open, 9: e268641. Available from: https://doi.org/10.1001/jamanetworkopen.2026.8641

Ref. 368. Chan FY, et al. (2025) PLOS Glob Public Health, 5: e0004357. Available from: https://doi.org/10.1371/journal.pgph.0004357

Ref. 369. Morris RD (1995) Environ Health Perspect, 103 Suppl 8: 225. Available from: https://doi.org/10.1289/ehp.95103s8225

Ref. 370. Levin R, et al. (2024) J Expo Sci Environ Epidemiol, 34: 3. Available from: https://doi.org/10.1038/s41370-023-00597-z

Ref. 371. van Gerwen M, et al. (2023) EBioMedicine, 97: 104831. Available from: https://doi.org/10.1016/j.ebiom.2023.104831

Ref. 372. Liu B, et al. (2024) JAMA Netw Open, 7: e243127. Available from: https://doi.org/10.1001/jamanetworkopen.2024.3127

Ref. 373. Rhee J, et al. (2024) Environ Int, 192: 109058. Available from: https://doi.org/10.1016/j.envint.2024.109058

Ref. 374. Hu XC, et al. (2016) Environ Sci Technol Lett, 3: 344. Available from: https://doi.org/10.1021/acs.estlett.6b00260

Ref. 375. Zahm S, et al. (2024) Lancet Oncol, 25: 16. Available from: https://doi.org/10.1016/S1470-2045(23)00622-8

Ref. 376. Ernhofer B, et al. (2025) Journal of Hazardous Materials, 495: 139129. Available from: https://doi.org/10.1016/j.jhazmat.2025.139129

Ref. 377. Mishra SK, et al. (2025) Molecular Cancer, 24: 248. Available from: https://doi.org/10.1186/s12943-025-02409-4

Ref. 378. Klingelhöfer D, et al. (2020) Water Res, 170: 115358. Available from: https://doi.org/10.1016/j.watres.2019.115358

Ref. 379. Malafaia G, et al. (2023) TrAC Trends in Analytical Chemistry, 161: 117016. Available from: https://doi.org/10.1016/j.trac.2023.117016

Ref. 380. Chen Q, et al. (2022) Environmental Sciences Europe, 34: 25. Available from: https://doi.org/10.1186/s12302-022-00605-3

Ref. 381. Li L, et al. (2025) Proc Natl Acad Sci U S A, 122: e2408084121. Available from: https://doi.org/10.1073/pnas.2408084121

Ref. 382. Consumer Reports. Dangerous Chemicals Were Detected in 100% of the Braiding Hair We Tested. Accessed: June 30, 2026. Available from: https://www.consumerreports.org/health/wigs-hair-extensions/dangerous-chemicals-detected-in-braiding-hair-cr-tested-a4850978424/

Ref. 383. Consumer Reports. We Found Heavy Metals and VOCs in CR’s Follow-Up Braiding Hair Investigation. Accessed: June 30, 2026. Available from: https://www.consumerreports.org/health/wigs-hair-extensions/braiding-hair-heavy-metals-vocs-follow-up-test-a9549045438/

Ref. 384. Bertrand KA, et al. (2023) Environ Res, 239: 117228. Available from: https://doi.org/10.1016/j.envres.2023.117228

Ref. 385. Abbott NA, et al. (2025) Environ Sci Technol, 59: 45. Available from: https://doi.org/10.1021/acs.est.4c05094

Ref. 386. Domingo JL, et al. (2020) Environmental Research, 186: 109495. Available from: https://doi.org/10.1016/j.envres.2020.109495

Ref. 387. Eom SY, et al. (2018) Environ Health Toxicol, 33: e2018004. Available from: https://doi.org/10.5620/eht.e2018004

Ref. 388. American Lung Association. State of the Air 2026 Report. Accessed: June 30, 2026. Available from: https://www.lung.org/getmedia/32f0646d-c5de-4501-b0ac-07cd63c974d4/State-of-the-Air-2026-Report.pdf

Ref. 389. CNN. Tracking wildfires and smoke across the US in maps and charts. Accessed: June 30, 2026. Available from: https://www.cnn.com/us/us-wildfires-tracker-maps-charts-vis

Ref. 390. Mueller JT, et al. (2021) Nat Commun, 12: 3544. Available from: https://doi.org/10.1038/s41467-021-23898-z

Ref. 391. Dai MQ, et al. (2025) Environ Health Perspect, 133: 67003. Available from: https://doi.org/10.1289/ehp14793

Ref. 392. Baan R, et al. (2009) Lancet Oncol, 10: 1143. Available from: https://doi.org/10.1016/s1470-2045(09)70358-4

Ref. 393. Lesinski JD, et al. (2026) The Lancet Oncology, 27: 79. Available from: https://doi.org/10.1016/S1470-2045(25)00593-5

Ref. 394. McDermott JE, et al. (2024) J Proteome Res, 23: 1547. Available from: https://doi.org/10.1021/acs.jproteome.3c00418

Ref. 395. Ogunlusi O, et al. (2025) Oncogene, 44: 4491. Available from: https://doi.org/10.1038/s41388-025-03597-5

Ref. 396. Frost DM, et al. (2023) Curr Opin Psychol, 51: 101579. Available from: https://doi.org/10.1016/j.copsyc.2023.101579

Ref. 397. Boutelle KN, et al. (2000) Prev Med, 30: 217. Available from: https://doi.org/10.1006/pmed.1999.0618

Ref. 398. Ng DM, et al. (2003) Health Psychol, 22: 638. Available from: https://doi.org/10.1037/0278-6133.22.6.638

Ref. 399. Goel N, et al. (2024) J Clin Oncol, 42: 3618. Available from: https://doi.org/10.1200/JCO.23.02780

Ref. 400. Plascak JJ, et al. (2022) Cancer, 128: 131. Available from: https://doi.org/10.1002/cncr.33900

Ref. 401. Krueger PM, et al. (2008) Am J Public Health, 98: 889. Available from: https://doi.org/10.2105/AJPH.2007.114454

Ref. 402. Herbetko K, et al. (2026) Int J Mol Sci, 27. Available from: https://doi.org/10.3390/ijms27020686

Ref. 403. Dai S, et al. (2020) Front Oncol, 10: 1492. Available from: https://doi.org/10.3389/fonc.2020.01492

Ref. 404. McEwen BS, et al. (1993) Arch Intern Med, 153: 2093. Available from: https://doi.org/10.1001/archinte.1993.00410180039004

Ref. 405. Llanos AAM, et al. (2022) Front Oncol, 12: 857548. Available from: https://doi.org/10.3389/fonc.2022.857548

Ref. 406. Guan Y, et al. (2025) JAMA Network Open, 8: e2528019. Available from: https://doi.org/10.1001/jamanetworkopen.2025.28019

Ref. 407. Xing CY, et al. (2020) Breast Cancer Res Treat, 184: 901. Available from: https://doi.org/10.1007/s10549-020-05901-1

Ref. 408. Gormley M, et al. (2025) npj Breast Cancer, 11: 90. Available from: https://doi.org/10.1038/s41523-025-00812-0

Ref. 409. Barrett M, et al. (2022) Trends in Molecular Medicine, 28: 1040. Available from: https://doi.org/10.1016/j.molmed.2022.09.006

Ref. 410. Harris AR, et al. (2025) JAMA Netw Open, 8: e2459754. Available from: https://doi.org/10.1001/jamanetworkopen.2024.59754

Ref. 411. Beese S, et al. (2022) Int J Environ Res Public Health, 19. Available from: https://doi.org/10.3390/ijerph192417006

Ref. 412. Teferi HM, et al. (2026) Psychoneuroendocrinology, 183: 107661. Available from: https://doi.org/10.1016/j.psyneuen.2025.107661

Ref. 413. Obeng-Gyasi S, et al. (2021) npj Breast Cancer, 7: 100. Available from: https://doi.org/10.1038/s41523-021-00309-6

Ref. 414. Stabellini N, et al. (2023) JNCI Cancer Spectrum, 7: pkad005. Available from: https://doi.org/10.1093/jncics/pkad005

Ref. 415. Shen J, et al. (2025) Sci Rep, 15: 37505. Available from: https://doi.org/10.1038/s41598-025-21510-8

Ref. 416. Guan Y, et al. (2024) Cancers (Basel), 16. Available from: https://doi.org/10.3390/cancers16183235

Ref. 417. Sanogo F, et al. (2026) Cancer Res Commun, 6: 698. Available from: https://doi.org/10.1158/2767-9764.CRC-25-0388

Ref. 418. Jahanfar S, et al. (2024) Front Glob Womens Health, 5: 1487820. Available from: https://doi.org/10.3389/fgwh.2024.1487820

Ref. 419. Kamani M, et al. (2022) Ecancermedicalscience, 16: 1416. Available from: https://doi.org/10.3332/ecancer.2022.1416

Ref. 420. Ferguson D, et al. (2026) Maturitas, 208: 108898. Available from: https://doi.org/10.1016/j.maturitas.2026.108898

Ref. 421. Hadizadeh F, et al. (2025) JAMA Oncol, 11: 1497. Available from: https://doi.org/10.1001/jamaoncol.2025.4480

Ref. 422. Nichols HB, et al. (2019) Ann Intern Med, 170: 22. Available from: https://doi.org/10.7326/M18-1323

Ref. 423. Subramani R, et al. (2017) Prog Mol Biol Transl Sci, 151: 81. Available from: https://doi.org/10.1016/bs.pmbts.2017.07.006

Ref. 424. Zhang S, et al. (2025) Ther Adv Med Oncol, 17: 17588359251369973. Available from: https://doi.org/10.1177/17588359251369973

Ref. 425. Obeagu EI, et al. (2024) Ann Med Surg (Lond), 86: 2805. Available from: https://doi.org/10.1097/MS9.0000000000001914

Ref. 426. Sierra-Roca J, et al. (2025) Pathogens, 14. Available from: https://doi.org/10.3390/pathogens14090946

Ref. 427. Lambrinoudaki I, et al. (2026) J Clin Endocrinol Metab, 111: e974. Available from: https://doi.org/10.1210/clinem/dgaf638

Ref. 428. National Heart, Lung, and Blood Institute. Women’s Health Initiative (WHI). Accessed: June 30, 2026. Available from: https://www.nhlbi.nih.gov/science/womens-health-initiative-whi

Ref. 429. O’Brien KM, et al. (2025) Lancet Oncol, 26: 911. Available from: https://doi.org/10.1016/S1470-2045(25)00211-6

Ref. 430. Bollam R, et al. (2026) Maturitas, 208: 108894. Available from: https://doi.org/10.1016/j.maturitas.2026.108894

Ref. 431. Thorat MA, et al. (2026) Mol Oncol, 20: 117. Available from: https://doi.org/10.1002/1878-0261.70158

Ref. 432. U.S Preventive Services Task Force (2022) JAMA, 328: 1740. Available from: https://doi.org/10.1001/jama.2022.18625

Ref. 433. US Food and Drug Administration. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. Accessed: June 30, 2026. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products

Ref. 434. Jackson SS, et al. (2022) Trends Cancer, 8: 273. Available from: https://doi.org/10.1016/j.trecan.2022.01.005

Ref. 435. Unger CA (2016) Transl Androl Urol, 5: 877. Available from: https://doi.org/10.21037/tau.2016.09.04

Ref. 436. Awadalla R, et al. (2026) N Z Med J, 139: 81. Available from: https://doi.org/10.26635/6965.7324

Ref. 437. Tewari S, et al. (2026) Obstet Gynecol Clin North Am, 53: 323. Available from: https://doi.org/10.1016/j.ogc.2026.01.004

Ref. 438. Aranda-Gutierrez A, et al. (2025) Sex Health, 22. Available from: https://doi.org/10.1071/SH25124

Ref. 439. Duffy SW, et al. (2026) Nat Rev Clin Oncol, 23: 201. Available from: https://doi.org/10.1038/s41571-025-01112-z

Ref. 440. Kaneko M, et al. (2026) Ther Adv Gastroenterol, 19: 17562848261454186. Available from: https://doi.org/10.1177/17562848261454186

Ref. 441. Botteri E, et al. (2026) Ann Intern Med, 179: 804. Available from: https://doi.org/10.7326/ANNALS-25-05456

Ref. 442. Bandi P, et al. (2025) JAMA, 334: 2225. Available from: https://doi.org/10.1001/jama.2025.19798

Ref. 443. Star J, et al. (2025) JAMA, 334: 827. Available from: https://doi.org/10.1001/jama.2025.10618

Ref. 444. Schafer EJ, et al. (2025) JAMA, 334: 824. Available from: https://doi.org/10.1001/jama.2025.9147

Ref. 445. Harper L, et al. (2026) Maturitas, 208: 108916. Available from: https://doi.org/10.1016/j.maturitas.2026.108916

Ref. 446. Tosteson ANA, et al. (2026) Ann Intern Med, 179: 486. Available from: https://doi.org/10.7326/ANNALS-25-00792

Ref. 447. Perkins RB, et al. (2026) CA Cancer J Clin, 76: e70041. Available from: https://doi.org/10.3322/caac.70041

Ref. 448. National Cancer Institute. SHIP Trial – About the Study. Accessed: June 30, 2026. Available from: https://prevention.cancer.gov/research-areas/networks-consortia-programs/last-mile/ship-trial

Ref. 449. Gupta S, et al. (2026) JAMA, 335: 1499. Available from: https://doi.org/10.1001/jama.2026.3414

Ref. 450. Castle PE, et al. (2026) J Natl Cancer Inst, 118: 325. Available from: https://doi.org/10.1093/jnci/djaf317

Ref. 451. Gottschlich A, et al. (2026) JAMA Netw Open, 9: e261304. Available from: https://doi.org/10.1001/jamanetworkopen.2026.1304

Ref. 452. Potter AL, et al. (2024) J Clin Oncol, 42: 2026. Available from: https://doi.org/10.1200/JCO.23.01780

Ref. 453. Manful A, et al. (2026) Chest, 169: 1750. Available from: https://doi.org/10.1016/j.chest.2026.01.006

Ref. 454. Gu T, et al. (2024) JAMA Netw Open, 7: e2451827. Available from: https://doi.org/10.1001/jamanetworkopen.2024.51827

Ref. 455. Zhang H, et al. (2025) Cancer, 131: e35852. Available from: https://doi.org/10.1002/cncr.35852

Ref. 456. Lui ML, et al. (2026) Cancer Epidemiol Biomarkers Prev, 35: 456. Available from: https://doi.org/10.1158/1055-9965.EPI-25-1457

Ref. 457. Vinson AH, et al. (2025) JAMA Netw Open, 8: e2457290. Available from: https://doi.org/10.1001/jamanetworkopen.2024.57290

Ref. 458. Ewing AP, et al. (2026) JAMA Netw Open, 9: e266000. Available from: https://doi.org/10.1001/jamanetworkopen.2026.6000

Ref. 459. Ciemins EL, et al. (2024) JAMA Netw Open, 7: e242693. Available from: https://doi.org/10.1001/jamanetworkopen.2024.2693

Ref. 460. Tasevac B, et al. (2024) CHEST Pulmonary, 2: 100051. Available from: https://doi.org/10.1016/j.chpulm.2024.100051

Ref. 461. Bhojani N, et al. (2025) Prostate Cancer Prostatic Dis, 28: 400. Available from: https://doi.org/10.1038/s41391-024-00843-x

Ref. 462. Lacombe-Duncan A, et al. (2025) Urol Oncol, 43: 664 e1. Available from: https://doi.org/10.1016/j.urolonc.2025.07.017

Ref. 463. Pradhan P, et al. (2025) JAMA Netw Open, 8: e2537905. Available from: https://doi.org/10.1001/jamanetworkopen.2025.37905

Ref. 464. Galoosian A, et al. (2025) JAMA, 334: 778. Available from: https://doi.org/10.1001/jama.2025.12049

Ref. 465. Korostoff-Larsson O, et al. (2026) JAMA Netw Open, 9: e267122. Available from: https://doi.org/10.1001/jamanetworkopen.2026.7122

Ref. 466. Miller DP, et al. (2025) JAMA, 334: 1807. Available from: https://doi.org/10.1001/jama.2025.17281

Ref. 467. Freeman HP, et al. (2011) Cancer, 117: 3539. Available from: https://doi.org/10.1002/cncr.26262

Ref. 468. Nelson HD, et al. (2025) JAMA Intern Med, 185: 976. Available from: https://doi.org/10.1001/jamainternmed.2025.1590

Ref. 469. Coronado GD, et al. (2025) JAMA Netw Open, 8: e250928. Available from: https://doi.org/10.1001/jamanetworkopen.2025.0928

Ref. 470. Ramai D, et al. (2026) Gastroenterology. Available from: https://doi.org/10.1053/j.gastro.2026.02.047

Ref. 471. Montealegre JR, et al. (2025) JAMA Intern Med, 185: 1119. Available from: https://doi.org/10.1001/jamainternmed.2025.2971

Ref. 472. Tangka FKL, et al. (2025) Cancer, 131: e70031. Available from: https://doi.org/10.1002/cncr.70031

Ref. 473. Carter-Bawa L, et al. (2025) BMC Public Health, 25: 379. Available from: https://doi.org/10.1186/s12889-025-21623-9

Ref. 474. Dadha P, et al. (2026) PEC Innovation, 8: 100470. Available from: https://doi.org/10.1016/j.pecinn.2026.100470

Ref. 475. Savas LS, et al. (2026) Front Oncol, 16: 1687113. Available from: https://doi.org/10.3389/fonc.2026.1687113

Ref. 476. Afshari Mirak S, et al. (2025) Radiology, 314: e232625. Available from: https://doi.org/10.1148/radiol.232625

Ref. 477. Christensen EW, et al. (2026) AJR Am J Roentgenol, 226: e2533587. Available from: https://doi.org/10.2214/AJR.25.33587

Ref. 478. Gommers J, et al. (2026) Lancet, 407: 505. Available from: https://doi.org/10.1016/S0140-6736(25)02464-X

Ref. 479. Lang K, et al. (2023) Lancet Oncol, 24: 936. Available from: https://doi.org/10.1016/S1470-2045(23)00298-X

Ref. 480. Elias-Cabot E, et al. (2026) Nat Med, 32: 1296. Available from: https://doi.org/10.1038/s41591-026-04277-x

Ref. 481. Kelly CJ, et al. (2026) Nat Cancer, 7: 494. Available from: https://doi.org/10.1038/s43018-026-01127-0

Ref. 482. Liang Y, et al. (2026) Nat Commun, 17. Available from: https://doi.org/10.1038/s41467-026-69212-7

Ref. 483. Adams SJ, et al. (2023) J Am Coll Radiol, 20: 232. Available from: https://doi.org/10.1016/j.jacr.2022.08.006

Ref. 484. US Food and Drug Administration. Radiological Computer-Assisted Diagnostic Software For Lesions Suspicious Of Cancer: RevealAI-Lung. Accessed: June 30, 2026. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf25/K251769.pdf

Ref. 485. US Food and Drug Administration. Radiological Computer Assisted Detection And Diagnosis Software: eyonis® LCS 1.1. Accessed: June 30, 2026. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf25/K251474.pdf

Ref. 486. Lowry KP, et al. (2026) J Natl Cancer Inst, 118: 392. Available from: https://doi.org/10.1093/jnci/djag002

Ref. 487. Duan Z, et al. (2025) Cell Rep Med, 6: 102465. Available from: https://doi.org/10.1016/j.xcrm.2025.102465

Ref. 488. Ogu JC, et al. (2025) Breast Cancer Res Treat, 215: 25. Available from: https://doi.org/10.1007/s10549-025-07870-9

Ref. 489. Kuperberg SJ, et al. (2025) Cancer Innov, 4: e70019. Available from: https://doi.org/10.1002/cai2.70019

Ref. 490. Bryan ME, et al. (2025) Clin Cancer Res, 31: 3483. Available from: https://doi.org/10.1158/1078-0432.CCR-24-2525

Ref. 491. Das D, et al. (2026) J Natl Cancer Inst, 118: 58. Available from: https://doi.org/10.1093/jnci/djaf249

Ref. 492. Mannucci A, et al. (2026) Gastroenterology, 170: 330. Available from: https://doi.org/10.1053/j.gastro.2025.08.013

Ref. 493. Cameron JM, et al. (2026) Cancer Prev Res (Phila), 19: 145. Available from: https://doi.org/10.1158/1940-6207.CAPR-25-0286

Ref. 494. Kahwati LC, et al. (2025) Ann Intern Med, 178: 1591. Available from: https://doi.org/10.7326/ANNALS-25-01877

Ref. 495. National Health Service (UK). NHS-Galleri trial reports fewer diagnoses of the most advanced cancers. Accessed: June 30, 2026. Available from: https://www.nhs-galleri.org/trial-updates/nhs-galleri-trial-reports-fewer-diagnoses-of-the-most-advanced-cancers

Ref. 496. LeeVan E, et al. (2025) Cancer Epidemiol Biomarkers Prev, 34: 1787. Available from: https://doi.org/10.1158/1055-9965.EPI-25-0903

Ref. 497. Chhatwal J, et al. (2025) Cancer, 131: e70075. Available from: https://doi.org/10.1002/cncr.70075

Ref. 498. Meester RGS, et al. (2026) J Natl Cancer Inst, 118: 113. Available from: https://doi.org/10.1093/jnci/djaf277

Ref. 499. Fergus KB, et al. (2026) JAMA Intern Med, 186: 344. Available from: https://doi.org/10.1001/jamainternmed.2025.7323

Ref. 500. O’Brien KM, et al. (2025) JAMA Oncol, 11: 1458. Available from: https://doi.org/10.1001/jamaoncol.2025.3875

Ref. 501. Esserman LJ, et al. (2026) JAMA, 335: 763. Available from: https://doi.org/10.1001/jama.2025.24784

Ref. 502. Alagoz O, et al. (2026) JAMA Netw Open, 9: e2552944. Available from: https://doi.org/10.1001/jamanetworkopen.2025.52944

Ref. 503. Vogel-Claussen J, et al. (2025) Lancet Oncol, 26: 1541. Available from: https://doi.org/10.1016/S1470-2045(25)00490-5

Ref. 504. Campoy S, et al. (2026) J Natl Cancer Inst, 118: 589. Available from: https://doi.org/10.1093/jnci/djaf349

Ref. 505. Vassy JL, et al. (2026) Nat Cancer, 7: 352. Available from: https://doi.org/10.1038/s43018-025-01103-0

Ref. 506. Chabrun F, et al. (2026) Nat Med, 32: 1745. Available from: https://doi.org/10.1038/s41591-026-04304-x

Ref. 507. Kerlikowske K, et al. (2025) NPJ Digit Med, 8: 771. Available from: https://doi.org/10.1038/s41746-025-02130-y

Ref. 508. Gu M, et al. (2026) Nat Genet, 58: 704. Available from: https://doi.org/10.1038/s41588-026-02505-1

Ref. 509. D’Alise AM, et al. (2026) Nat Med, 32: 1002. Available from: https://doi.org/10.1038/s41591-025-04182-9

Ref. 510. Zhu Z, et al. (2026) Trends Mol Med. Available from: https://doi.org/10.1016/j.molmed.2026.02.004

Ref. 511. O’Reilly C, et al. (2026) JAMA Surg, 161: 260. Available from: https://doi.org/10.1001/jamasurg.2025.5929

Ref. 512. American Association for Cancer Research. AACR Pediatric Cancer Progress Report 2025. Accessed: June 30, 2026. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2025/12/AACR_PCPR_2025.pdf

Ref. 513. American Association for Cancer Research. AACR Cancer Progress Report 2025. Accessed: June 30, 2026. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2025/09/AACR_CPR_2025.pdf

Ref. 514. Barreto RB, et al. (2025) JCO Glob Oncol, 11: e2500326. Available from: https://doi.org/10.1200/GO-25-00326

Ref. 515. Abu Rous F, et al. (2024) JAMA Oncol, 10: 416. Available from: https://doi.org/10.1001/jamaoncol.2023.5778

Ref. 516. Adashek JJ, et al. (2019) Nat Rev Clin Oncol, 16: 773. Available from: https://doi.org/10.1038/s41571-019-0262-9

Ref. 517. Kingwell K (2022) Nat Rev Drug Discov, 21: 702. Available from: https://doi.org/10.1038/d41573-022-00144-9

Ref. 518. Cuthbertson J, et al. (2026) Nat Rev Drug Discov, 25: 262. Available from: https://doi.org/10.1038/d41573-025-00199-4

Ref. 519. Purja S, et al. (2026) J Natl Cancer Inst. Available from: https://doi.org/10.1093/jnci/djag129

Ref. 520. Nikanjam M, et al. (2025) CA Cancer J Clin, 75: 243. Available from: https://doi.org/10.3322/caac.21880

Ref. 521. Wagner MJ, et al. (2021) J Immunother Cancer, 9. Available from: https://doi.org/10.1136/jitc-2021-002990

Ref. 522. National Cancer Institute. NCI-MATCH Trial (Molecular Analysis for Therapy Choice). Accessed: June 30, 2026. Available from: https://www.cancer.gov/research/infrastructure/clinical-trials/featured/nci-match

Ref. 523. National Cancer Institute. Lung-MAP Clinical Trial. Accessed: June 30, 2026. Available from: https://www.cancer.gov/types/lung/research/lung-map

Ref. 524. Oxford Population Health. RECOVERY Trial. Accessed: June 30, 2026. Available from: https://www.recoverytrial.net/

Ref. 525. Wang H, et al. (2019) Curr Breast Cancer Rep, 11: 303. Available from: https://doi.org/10.1007/s12609-019-00334-2

Ref. 526. Dy GK, et al. (2023) J Clin Oncol, 41: 3311. Available from: https://doi.org/10.1200/JCO.22.02524

Ref. 527. Sicklick JK, et al. (2026) J Clin Oncol, 44: 540. Available from: https://doi.org/10.1200/JCO-25-01453

Ref. 528. Verkerk K, et al. (2026) Nature, 653: 558. Available from: https://doi.org/10.1038/s41586-026-10405-x

Ref. 529. Marchetti P, et al. (2025) Nature Medicine, 31: 3514. Available from: https://doi.org/10.1038/s41591-025-03918-x

Ref. 530. Lin FP, et al. (2026) JAMA Oncol, 12: 458. Available from: https://doi.org/10.1001/jamaoncol.2026.0127

Ref. 531. To TM, et al. (2026) Cancer Research Communications, 6: 191. Available from: https://doi.org/10.1158/2767-9764.CRC-25-0225

Ref. 532. US Food and Drug Administration. Project Optimus. Accessed: June 30, 2026. Available from: https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus

Ref. 533. Marret G, et al. (2025) Cancer Cell, 43: 597. Available from: https://doi.org/10.1016/j.ccell.2025.02.019

Ref. 534. Wildiers H, et al. (2026) JAMA Oncol, 12: 200. Available from: https://doi.org/10.1001/jamaoncol.2025.5376

Ref. 535. Orcutt X, et al. (2025) Nat Med, 31: 457. Available from: https://doi.org/10.1038/s41591-024-03352-5

Ref. 536. Gueguen L, et al. (2025) NPJ Precis Oncol, 9: 28. Available from: https://doi.org/10.1038/s41698-025-00806-y

Ref. 537. Bickell NA, et al. (2024) JAMIA Open, 7: ooae131. Available from: https://doi.org/10.1093/jamiaopen/ooae131

Ref. 538. Katsoulakis E, et al. (2024) NPJ Digit Med, 7: 77. Available from: https://doi.org/10.1038/s41746-024-01073-0

Ref. 539. Eckardt J-N, et al. (2026) Nature Reviews Cancer, 26: 351. Available from: https://doi.org/10.1038/s41568-026-00912-4

Ref. 540. Unger JM, et al. (2024) J Clin Oncol, 42: 2139. Available from: https://doi.org/10.1200/JCO.23.01030

Ref. 541. Bowling H, et al. (2026) Nat Rev Drug Discov, 25: 345. Available from: https://doi.org/10.1038/d41573-025-00208-6

Ref. 542. Balogh EP, et al. (2025) JCO Oncol Pract, 21: 1746. Available from: https://doi.org/10.1200/OP-25-00233

Ref. 543. US Food and Drug Administration. Drug Trials Snapshots: VYLOY. Accessed: June 30, 2026. Available from: https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-vyloy

Ref. 544. US Food and Drug Administration. Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies. Accessed: June 30, 2026. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies

Ref. 545. Chua AV, Jr., et al. (2025) JCO Oncol Pract, 21: 408. Available from: https://doi.org/10.1200/op.24.00033

Ref. 546. Taira DA, et al. (2024) JAMA Netw Open, 7: e2442204. Available from: https://doi.org/10.1001/jamanetworkopen.2024.42204

Ref. 547. Gopishetty S, et al. (2020) Am J Transl Res, 12: 5977. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7540092/

Ref. 548. Kirkwood MK, et al. (2025) JCO Oncol Pract, 21: 427. Available from: https://doi.org/10.1200/OP.24.00261

Ref. 549. Unger JM, et al. (2025) CA Cancer J Clin, 75: 341. Available from: https://doi.org/10.3322/caac.70006

Ref. 550. Lee H, et al. (2024) JAMA Oncol, 10: 652. Available from: https://doi.org/10.1001/jamaoncol.2023.7314

Ref. 551. Williams CP, et al. (2026) JNCI Cancer Spectr, 10. Available from: https://doi.org/10.1093/jncics/pkag048

Ref. 552. Abbidi SR, et al. (2026) Trials, 27: 217. Available from: https://doi.org/10.1186/s13063-026-09537-2

Ref. 553. Chow EJ, et al. (2023) J Clin Oncol, 41: 2248. Available from: https://doi.org/10.1200/JCO.22.02423

Ref. 554. Gong G, et al. (2026) JCO Clinical Cancer Informatics, 10: e2500262. Available from: https://doi.org/10.1200/CCI-25-00262

Ref. 555. O’Reilly EM, et al. (2026) N Engl J Med. Available from: https://doi.org/10.1056/NEJMoa2605555

Ref. 556. American Association for Cancer Research. AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care. Accessed: June 30, 2026. Available from: https://www.aacr.org/professionals/research/aacr-covid-19-and-cancer-report-2022/

Ref. 557. Aiyegbusi OL, et al. (2024) Nat Med, 30: 3075. Available from: https://doi.org/10.1038/s41591-024-03323-w

Ref. 558. Haddad TC, et al. (2026) JAMA Netw Open, 9: e2617204. Available from: https://doi.org/10.1001/jamanetworkopen.2026.17204

Ref. 559. Friedman DR, et al. (2026) JNCI: Journal of the National Cancer Institute, 118: 68. Available from: https://doi.org/10.1093/jnci/djaf279

Ref. 560. Bloomberg New Economy International Cancer C, et al. (2024) Cancer Discov, 14: 2317. Available from: https://doi.org/10.1158/2159-8290.CD-24-1288

Ref. 561. Izarn F, et al. (2025) ESMO Open, 10: 104086. Available from: https://doi.org/10.1016/j.esmoop.2024.104086

Ref. 562. Higgins MI, et al. (2026) Prostate Cancer and Prostatic Diseases. Available from: https://doi.org/10.1038/s41391-026-01085-9

Ref. 563. Padrão N, et al. (2026) Nature, 649: 1013. Available from: https://doi.org/10.1038/s41586-025-09869-0

Ref. 564. Martling A, et al. (2025) N Engl J Med, 393: 1051. Available from: https://doi.org/10.1056/NEJMoa2504650

Ref. 565. Oncology (Cancer)/Hematologic Malignancies Approval Notifications. Accessed: June 30, 2026. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications?randparam=522836

Ref. 566. Kim RB, et al. (2024) J Racial Ethn Health Disparities, 00: 10.1007/s40615. Available from: https://doi.org/10.1007/s40615-024-02077-y

Ref. 567. Bullard AJ, et al. (2026) JAMA Netw Open, 9: e2621585. Available from: https://doi.org/10.1001/jamanetworkopen.2026.21585

Ref. 568. Tamirisa N, et al. (2023) Ann Surg: 00. Available from: https://doi.org/10.1097/SLA.0000000000006177

Ref. 569. Hooda Z, et al. (2025) Ann Thorac Surg. Available from: https://doi.org/10.1016/j.athoracsur.2025.03.042

Ref. 570. Lyons JM, et al. (2025) Cancers (Basel), 17. Available from: https://doi.org/10.3390/cancers17020207

Ref. 571. Hohenleitner JT, et al. (2026) JAMA Surg, 161: 460. Available from: https://doi.org/10.1001/jamasurg.2026.0057

Ref. 572. Tfayli AH, et al. (2025) Cancer, 131: e35590. Available from: https://doi.org/10.1002/cncr.35590

Ref. 573. Cherny NI, et al. (2025) Ann Oncol, 36: 247. Available from: https://doi.org/10.1016/j.annonc.2024.12.005

Ref. 574. Patel VR, et al. (2025) Ann Surg, 281: 711. Available from: https://doi.org/10.1097/SLA.0000000000006516

Ref. 575. Freeman JQ, et al. (2026) JAMA Netw Open, 9: e268908. Available from: https://doi.org/10.1001/jamanetworkopen.2026.8908

Ref. 576. Fox AH, et al. (2026) JAMA Oncol. Available from: https://doi.org/10.1001/jamaoncol.2026.1080

Ref. 577. Hage Chehade C, et al. (2026) JAMA Netw Open, 9: e265585. Available from: https://doi.org/10.1001/jamanetworkopen.2026.5585

Ref. 578. Ali MS, et al. (2025) Immunotherapy, 17: 37. Available from: https://doi.org/10.1080/1750743X.2025.2452836

Ref. 579. Burotto M, et al. (2019) Semin Oncol, 46: 83. Available from: https://doi.org/10.1053/j.seminoncol.2019.01.002

Ref. 580. Gros L, et al. (2026) Lancet Reg Health Am, 56: 101428. Available from: https://doi.org/10.1016/j.lana.2026.101428

Ref. 581. Sun V, et al. (2025) NPJ Digit Med, 8: 555. Available from: https://doi.org/10.1038/s41746-025-01961-z

Ref. 582. Topal H, et al. (2022) JAMA Netw Open, 5: e2248147. Available from: https://doi.org/10.1001/jamanetworkopen.2022.48147

Ref. 583. Son SY, et al. (2022) JAMA Surg, 157: 879. Available from: https://doi.org/10.1001/jamasurg.2022.2749

Ref. 584. Di Benedetto F, et al. (2023) JAMA Surg, 158: 46. Available from: https://doi.org/10.1001/jamasurg.2022.5697

Ref. 585. Bartels SAL, et al. (2023) Journal of Clinical Oncology, 41: 2159. Available from: https://doi.org/10.1200/Jco.22.01565

Ref. 586. Habermann EB, et al. (2025) J Am Coll Surg, 240: 95. Available from: https://doi.org/10.1097/XCS.0000000000001214

Ref. 587. Cercek A, et al. (2025) N Engl J Med, 392: 2297. Available from: https://doi.org/10.1056/NEJMoa2404512

Ref. 588. Kendra KL, et al. (2026) Nature Cancer, 7: 272. Available from: https://doi.org/10.1038/s43018-025-01113-y

Ref. 589. Lin YJ, et al. (2026) J Hepatol, 84: 316. Available from: https://doi.org/10.1016/j.jhep.2025.08.035

Ref. 590. Carleton N, et al. (2026) Clinical Cancer Research: OF1. Available from: https://doi.org/10.1158/1078-0432.CCR-25-4079

Ref. 591. Matsuo K, et al. (2026) JAMA Oncol, 12: 528. Available from: https://doi.org/10.1001/jamaoncol.2026.0170

Ref. 592. Gentilini OD, et al. (2023) JAMA Oncol, 9: 1557. Available from: https://doi.org/10.1001/jamaoncol.2023.3759

Ref. 593. Montagna G, et al. (2024) JAMA Oncol. Available from: https://doi.org/10.1001/jamaoncol.2024.0578

Ref. 594. Persano I, et al. (2026) Cancer Treat Rev, 143: 103092. Available from: https://doi.org/10.1016/j.ctrv.2026.103092

Ref. 595. Mamtani A, et al. (2026) JAMA Surg. Available from: https://doi.org/10.1001/jamasurg.2026.1268

Ref. 596. Bruna CL, et al. (2025) JAMA Surg, 160: 1299. Available from: https://doi.org/10.1001/jamasurg.2025.4054

Ref. 597. O’Leary D, et al. (2026) EClinicalMedicine, 92: 103683. Available from: https://doi.org/10.1016/j.eclinm.2025.103683

Ref. 598. Ahrenfeldt J, et al. (2026) Radiology, 318: e251485. Available from: https://doi.org/10.1148/radiol.251485

Ref. 599. Gulati S, et al. (2026) Ann Thorac Surg, 122: 178. Available from: https://doi.org/10.1016/j.athoracsur.2026.01.025

Ref. 600. Jimenez-Soto C, et al. (2025) Int J Surg. Available from: https://doi.org/10.1097/JS9.0000000000004070

Ref. 601. Wehrle CJ, et al. (2025) JCO Oncol Pract: OP2500550. Available from: https://doi.org/10.1200/OP-25-00550

Ref. 602. Sabajo CR, et al. (2026) JAMA Surg. Available from: https://doi.org/10.1001/jamasurg.2026.1519

Ref. 603. Zhang Y, et al. (2026) Cell Rep Med, 7: 102589. Available from: https://doi.org/10.1016/j.xcrm.2026.102589

Ref. 604. Sun Y, et al. (2026) JAMA Surg, 161: 223. Available from: https://doi.org/10.1001/jamasurg.2025.6256

Ref. 605. Abdel-Wahab M, et al. (2024) Lancet Oncol, 25: e545. Available from: https://doi.org/10.1016/S1470-2045(24)00407-8

Ref. 606. Wang K, et al. (2021) CA Cancer J Clin, 71: 437. Available from: https://doi.org/10.3322/caac.21689

Ref. 607. Kishan AU, et al. (2025) Clin Cancer Res, 31: 2530. Available from: https://doi.org/10.1158/1078-0432.CCR-24-3951

Ref. 608. Meattini I, et al. (2025) JAMA Oncol, 11: 329. Available from: https://doi.org/10.1001/jamaoncol.2024.5780

Ref. 609. Nakajima E, et al. (2026) JAMA Netw Open, 9: e264098. Available from: https://doi.org/10.1001/jamanetworkopen.2026.4098

Ref. 610. Jagsi R, et al. (2024) J Clin Oncol, 42: 390. Available from: https://doi.org/10.1200/JCO.23.02270

Ref. 611. Whelan TJ, et al. (2023) N Engl J Med, 389: 612. Available from: https://doi.org/10.1056/NEJMoa2302344

Ref. 612. Mann GB, et al. (2024) Lancet, 403: 261. Available from: https://doi.org/10.1016/S0140-6736(23)02476-5

Ref. 613. Williams LJ, et al. (2024) Lancet Oncol, 25: 1213. Available from: https://doi.org/10.1016/S1470-2045(24)00347-4

Ref. 614. Kunkler IH, et al. (2025) N Engl J Med, 393: 1771. Available from: https://doi.org/10.1056/NEJMoa2412225

Ref. 615. Frank SJ, et al. (2026) Lancet, 407: 174. Available from: https://doi.org/10.1016/S0140-6736(25)01962-2

Ref. 616. van Moorselaar RJA, et al. (2022) Eur Urol Open Sci, 35: 70. Available from: https://doi.org/10.1016/j.euros.2021.11.004

Ref. 617. Tsai CJ, et al. (2024) Lancet, 403: 171. Available from: https://doi.org/10.1016/S0140-6736(23)01857-3

Ref. 618. Palma DA, et al. (2020) J Clin Oncol, 38: 2830. Available from: https://doi.org/10.1200/JCO.20.00818

Ref. 619. Donovan EK, et al. (2024) JAMA Oncol, 00: e241796. Available from: https://doi.org/10.1001/jamaoncol.2024.1796

Ref. 620. Chinniah S, et al. (2022) Int J Radiat Oncol Biol Phys, 114: 684. Available from: https://doi.org/10.1016/j.ijrobp.2022.07.014

Ref. 621. Mansouri A, et al. (2025) Nat Rev Clin Oncol, 22: 327. Available from: https://doi.org/10.1038/s41571-025-01013-1

Ref. 622. Aizer AA, et al. (2026) JAMA, 335: 1127. Available from: https://doi.org/10.1001/jama.2026.0076

Ref. 623. Aizer AA, et al. (2025) J Clin Oncol, 43: 2986. Available from: https://doi.org/10.1200/JCO-25-00056

Ref. 624. Cho WK, et al. (2024) JAMA Oncol, 10: 737. Available from: https://doi.org/10.1001/jamaoncol.2024.0565

Ref. 625. Lee SF, et al. (2024) BMJ, 386: e079089. Available from: https://doi.org/10.1136/bmj-2023-079089

Ref. 626. Nilsson P, et al. (2026) The Lancet Oncology, 27: 293. Available from: https://doi.org/10.1016/S1470-2045(25)00656-4

Ref. 627. Brunt AM, et al. (2026) Lancet Oncol, 27: 686. Available from: https://doi.org/10.1016/S1470-2045(26)00076-8

Ref. 628. Chan K, et al. (2026) J Am Coll Surg, 242: 247. Available from: https://doi.org/10.1097/XCS.0000000000001637

Ref. 629. American Association for Cancer Research. AACR Cancer Progress Report 2018. Accessed: June 30, 2026. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2020/09/AACR_CPR_2018.pdf

Ref. 630. American Association for Cancer Research. AACR Cancer Progress Report 2021. Accessed: June 30, 2026. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2021/10/AACR_CPR_2021.pdf

Ref. 631. Varmenot N, et al. (2026) Clin Oncol (R Coll Radiol), 51: 104003. Available from: https://doi.org/10.1016/j.clon.2025.104003

Ref. 632. Tran HH, et al. (2025) Eur J Nucl Med Mol Imaging, 52: 2685. Available from: https://doi.org/10.1007/s00259-025-07103-7

Ref. 633. Ninatti G, et al. (2025) Cancers (Basel), 17. Available from: https://doi.org/10.3390/cancers17213412

Ref. 634. Prive BM, et al. (2026) Lancet Oncol, 27: 461. Available from: https://doi.org/10.1016/S1470-2045(25)00762-4

Ref. 635. Sandhu S, et al. (2026) Lancet Oncol, 27: 470. Available from: https://doi.org/10.1016/S1470-2045(26)00017-3

Ref. 636. DeVita VT, Jr., et al. (2008) Cancer Res, 68: 8643. Available from: https://doi.org/10.1158/0008-5472.CAN-07-6611

Ref. 637. Daneshmand S, et al. (2025) J Clin Oncol, 43: 3578. Available from: https://doi.org/10.1200/JCO-25-01651

Ref. 638. Janne PA, et al. (2026) N Engl J Med, 394: 27. Available from: https://doi.org/10.1056/NEJMoa2510308

Ref. 639. Zhou C, et al. (2026) N Engl J Med. Available from: https://doi.org/10.1056/NEJMoa2604461

Ref. 640. Gottschalk Z, et al. (2024) Curr Oncol Rep, 26: 959. Available from: https://doi.org/10.1007/s11912-024-01565-y

Ref. 641. Kasi PM, et al. (2024) Journal of Clinical Oncology, 42: 9. Available from: https://doi.org/10.1200/JCO.2024.42.3_suppl.9

Ref. 642. Bando H, et al. (2026) Nature Medicine. Available from: https://doi.org/10.1038/s41591-026-04428-0

Ref. 643. Carrasco R, et al. (2026) npj Precision Oncology, 10: 114. Available from: https://doi.org/10.1038/s41698-026-01337-w

Ref. 644. Dronca RS, et al. (2026) NEJM Catalyst, 7: CAT.25.0168. Available from: https://doi.org/doi:10.1056/CAT.25.0168

Ref. 645. Rosso C, et al. (2026) Pharmacogenomics, 27: 27. Available from: https://doi.org/10.1080/14622416.2026.2641748

Ref. 646. Nguyen-Hoang N, et al. (2026) Clinical Cancer Research. Available from: https://doi.org/10.1158/1078-0432.CCR-25-4721

Ref. 647. US Food and Drug Administration. Center for Drug Evaluation and Researc. Safety labeling update for capecitabine and fluorouracil (5-FU) on risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. Accessed: June 30, 2026. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/safety-labeling-update-capecitabine-and-fluorouracil-5-fu-risks-associated-dihydropyrimidine

Ref. 648. Podany EL, et al. (2025) JAMA Netw Open, 8: e2461899. Available from: https://doi.org/10.1001/jamanetworkopen.2024.61899

Ref. 649. Heath E, et al. (2024) Cancer Res Commun, 4: 2598. Available from: https://doi.org/10.1158/2767-9764.CRC-24-0321

Ref. 650. Kiel PJ, et al. (2025) J Cancer Educ. Available from: https://doi.org/10.1007/s13187-025-02775-z

Ref. 651. Vasan N, et al. (2019) Nature, 575: 299. Available from: https://doi.org/10.1038/s41586-019-1730-1

Ref. 652. Tufail M, et al. (2024) iScience, 27: 109979. Available from: https://doi.org/10.1016/j.isci.2024.109979

Ref. 653. Soragni A, et al. (2025) Nat Rev Cancer, 25: 613. Available from: https://doi.org/10.1038/s41568-025-00824-9

Ref. 654. American Cancer Society. Cancer Facts and Figures 2025. Accessed: June 30, 2026. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2025/2025-cancer-facts-and-figures-acs.pdf

Ref. 655. Avila J, et al. (2026) JAMA Netw Open, 9: e2612042. Available from: https://doi.org/10.1001/jamanetworkopen.2026.12042

Ref. 656. Jhaveri KL, et al. (2025) N Engl J Med, 392: 1189. Available from: https://doi.org/10.1056/NEJMoa2410858

Ref. 657. Kirmani N, et al. (2026) Cancer Treat Rev, 143: 103093. Available from: https://doi.org/10.1016/j.ctrv.2026.103093

Ref. 658. Campone M, et al. (2025) N Engl J Med, 393: 556. Available from: https://doi.org/10.1056/NEJMoa2505725

Ref. 659. Bili Newman A, et al. (2026) Cell Rep Med, 7: 102742. Available from: https://doi.org/10.1016/j.xcrm.2026.102742

Ref. 660. Valle I, et al. (2025) NPJ Breast Cancer, 11: 102. Available from: https://doi.org/10.1038/s41523-025-00829-5

Ref. 661. Heymach JV, et al. (2025) N Engl J Med, 392: 2321. Available from: https://doi.org/10.1056/NEJMoa2503704

Ref. 662. US Food and Drug Administration. FDA grants accelerated approval to zongertinib for non-squamous NSCLC with HER2 TKD activating mutations. Accessed: June 30, 2026. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zongertinib-non-squamous-nsclc-her2-tkd-activating-mutations

Ref. 663. US Food and Drug Administration. FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer. Accessed: June 30, 2026. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zongertinib-unresectable-or-metastatic-non-squamous-non-small-cell

Ref. 664. Heymach JV, et al. (2026) N Engl J Med, 394: 1675. Available from: https://doi.org/10.1056/NEJMoa2516969

Ref. 665. US Food and Drug Administration. FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer. Accessed: June 30, 2026. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-non-squamous-non-small-cell-lung-cancer

Ref. 666. Le X, et al. (2025) N Engl J Med, 393: 1819. Available from: https://doi.org/10.1056/NEJMoa2511065

Ref. 667. US Food and Drug Administration. FDA grants accelerated approval to sunvozertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations. Accessed: June 30, 2026. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sunvozertinib-metastatic-non-small-cell-lung-cancer-egfr-exon-20

Ref. 668. Yang JC, et al. (2025) J Clin Oncol, 43: 3198. Available from: https://doi.org/10.1200/JCO-25-00788

Ref. 669. Lorusso D, et al. (2026) The Lancet, 407: 1513. Available from: https://doi.org/10.1016/S0140-6736(26)00462-9

Ref. 670. Fizazi K, et al. (2026) Ann Oncol, 37: 53. Available from: https://doi.org/10.1016/j.annonc.2025.10.004

Ref. 671. Elmadani M, et al. (2025) Cancers (Basel), 17. Available from: https://doi.org/10.3390/cancers17101721

Ref. 672. US Food and Drug Administration. FDA approves zenocutuzumab-zbco for advanced, unresectable or metastatic cholangiocarcinoma. Accessed: June 30, 2026. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zenocutuzumab-zbco-advanced-unresectable-or-metastatic-cholangiocarcinoma

Ref. 673. Kim HJ, et al. (2023) Cancer Res Treat, 55: 41. Available from: https://doi.org/10.4143/crt.2021.1514

Ref. 674. Venneti S, et al. (2023) Cancer Discov, 13: 2370. Available from: https://doi.org/10.1158/2159-8290.CD-23-0131

Ref. 675. Arrillaga-Romany I, et al. (2024) J Clin Oncol, 42: 1542. Available from: https://doi.org/10.1200/JCO.23.01134

Ref. 676. Majzner RG, et al. (2022) Nature, 603: 934. Available from: https://doi.org/10.1038/s41586-022-04489-4

Ref. 677. Gomez S, et al. (2026) Nat Med, 32: 2481. Available from: https://doi.org/10.1038/s41591-026-04449-9

Ref. 678. Issa GC, et al. (2023) Nature, 615: 920. Available from: https://doi.org/10.1038/s41586-023-05812-3

Ref. 679. Yokoyama A, et al. (2005) Cell, 123: 207. Available from: https://doi.org/10.1016/j.cell.2005.09.025

Ref. 680. Issa GC, et al. (2025) J Clin Oncol, 43: 75. Available from: https://doi.org/10.1200/JCO.24.00826

Ref. 681. Kuhn MW, et al. (2016) Cancer Discov, 6: 1166. Available from: https://doi.org/10.1158/2159-8290.CD-16-0237

Ref. 682. Issa GC, et al. (2021) Leukemia, 35: 2482. Available from: https://doi.org/10.1038/s41375-021-01309-y

Ref. 683. Garber K (2024) Nat Rev Drug Discov, 23: 567. Available from: https://doi.org/10.1038/d41573-024-00106-3

Ref. 684. Wang ES, et al. (2025) J Clin Oncol, 43: 3381. Available from: https://doi.org/10.1200/JCO-25-01694

Ref. 685. Wang ES, et al. (2024) Lancet Oncol, 25: 1310. Available from: https://doi.org/10.1016/S1470-2045(24)00386-3

Ref. 686. Wang ES, et al. (2025) Journal of Clinical Oncology, 43: 3381. Available from: https://doi.org/10.1200/JCO-25-01694

Ref. 687. Wang ES, et al. (2026) Blood. Available from: https://doi.org/10.1182/blood.2026034043

Ref. 688. Pemmaraju N, et al. (2026) J Clin Oncol, 44: 861. Available from: https://doi.org/10.1200/JCO-25-02083

Ref. 689. American Association for Cancer Research. AACR Cancer Progress Report 2019. Accessed: June 30, 2026. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2020/09/AACR_CPR_2019.pdf

Ref. 690. US Food and Drug Administration. FDA grants accelerated approval to sonrotoclax for relapsed or refractory mantle cell lymphoma. Accessed: June 30, 2026. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sonrotoclax-relapsed-or-refractory-mantle-cell-lymphoma

Ref. 691. Liu J, et al. (2024) Blood, 143: 1825. Available from: https://doi.org/10.1182/blood.2023019706

Ref. 692. Hiam-Galvez KJ, et al. (2021) Nat Rev Cancer, 21: 345. Available from: https://doi.org/10.1038/s41568-021-00347-z

Ref. 693. Mishra AK, et al. (2022) Diseases, 10: 60. Available from: https://doi.org/10.3390/diseases10030060

Ref. 694. Kaufmann SHE (2019) Front Immunol, 10: 684. Available from: https://doi.org/10.3389/fimmu.2019.00684

Ref. 695. Marin-Acevedo JA, et al. (2021) J Hematol Oncol, 14: 45. Available from: https://doi.org/10.1186/s13045-021-01056-8

Ref. 696. Garon EB, et al. (2019) Journal of Clinical Oncology, 37: 2518. Available from: https://doi.org/10.1200/Jco.19.00934

Ref. 697. Wolchok JD, et al. (2025) N Engl J Med, 392: 11. Available from: https://doi.org/10.1056/NEJMoa2407417

Ref. 698. Long GV, et al. (2025) J Clin Oncol, 43: 938. Available from: https://doi.org/10.1200/JCO.24.00400

Ref. 699. US Food and Drug Administration. FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Accessed: June 30, 2026. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-paclitaxel-platinum-resistant-epithelial-ovarian-fallopian-tube-or

Ref. 700. Colombo N, et al. (2026) Lancet, 407: 1525. Available from: https://doi.org/10.1016/S0140-6736(26)00602-1

Ref. 701. US Food and Drug Administration. FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinoma. Accessed: June 30, 2026. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-resectable-gastric-or-gastroesophageal-junction-adenocarcinoma

Ref. 702. Janjigian YY, et al. (2025) N Engl J Med, 393: 217. Available from: https://doi.org/10.1056/NEJMoa2503701

Ref. 703. Wang Y, et al. (2025) NPJ Precis Oncol, 9: 346. Available from: https://doi.org/10.1038/s41698-025-01123-0

Ref. 704. Braun LM, et al. (2025) Trends Cancer, 11: 1058. Available from: https://doi.org/10.1016/j.trecan.2025.07.005

Ref. 705. Nielsen DL, et al. (2024) JAMA Oncol, 10: 1390. Available from: https://doi.org/10.1001/jamaoncol.2024.3065

Ref. 706. Ruiz-Esteves KN, et al. (2024) JAMA Oncol, 10: 1409. Available from: https://doi.org/10.1001/jamaoncol.2024.3104

Ref. 707. Wang Y, et al. (2025) N Engl J Med, 393: 2377. Available from: https://doi.org/10.1056/NEJMc2513984

Ref. 708. Taieb J, et al. (2025) JAMA Oncol, 11: 874. Available from: https://doi.org/10.1001/jamaoncol.2025.1646

Ref. 709. Garralda E, et al. (2026) Clinical Cancer Research, 32: 333. Available from: https://doi.org/10.1158/1078-0432.CCR-25-2312

Ref. 710. Ito K, et al. (2026) Nat Commun, 17. Available from: https://doi.org/10.1038/s41467-026-69680-x

Ref. 711. Wright SJ, et al. (2026) Nat Commun. Available from: https://doi.org/10.1038/s41467-026-74790-7

Ref. 712. Zhao J, et al. (2025) JAMA Netw Open, 8: e2519274. Available from: https://doi.org/10.1001/jamanetworkopen.2025.19274

Ref. 713. Haslam A, et al. (2025) Int J Cancer, 156: 2352. Available from: https://doi.org/10.1002/ijc.35347

Ref. 714. Sanjari Moghaddam A, et al. (2025) npj Breast Cancer, 12: 10. Available from: https://doi.org/10.1038/s41523-025-00873-1

Ref. 715. Aung TN, et al. (2025) Nature Genetics, 57: 2482. Available from: https://doi.org/10.1038/s41588-025-02351-7

Ref. 716. Dai Y, et al. (2025) Nature, 644: 537. Available from: https://doi.org/10.1038/s41586-025-09203-8

Ref. 717. DeVito N, et al. (2026) J Clin Oncol, 44: 529. Available from: https://doi.org/10.1200/JCO-25-01811

Ref. 718. Stone S, et al. (2026) Nature Reviews Cancer, 26: 137. Available from: https://doi.org/10.1038/s41568-025-00890-z

Ref. 719. Grippin AJ, et al. (2025) Nature, 647: 488. Available from: https://doi.org/10.1038/s41586-025-09655-y

Ref. 720. Heudel P-E, et al. (2026) European Journal of Cancer, 241. Available from: https://doi.org/10.1016/j.ejca.2026.116770

Ref. 721. Jee J, et al. (2026) Cancer Discov. Available from: https://doi.org/10.1158/2159-8290.CD-26-0403

Ref. 722. Thu MS, et al. (2026) Sci Rep, 16. Available from: https://doi.org/10.1038/s41598-026- 44743-7

Ref. 723. Schneider SM, et al. (2026) Nat Rev Cancer, 26: 480. Available from: https://doi.org/10.1038/ s41568-026-00921-3

Ref. 724. Pal SK, et al. (2026) Nat Med, 32: 1196. Available from: https://doi.org/10.1038/s41591-026- 04285-x

Ref. 725. Phelps CM, et al. (2025) Cell, 188: 5680. Available from: https://doi.org/10.1016/j.cell.2025.06.018

Ref. 726. Rohaan MW, et al. (2019) Virchows Arch, 474: 449. Available from: https://doi.org/10.1007/s00428-018-2484-0

Ref. 727. US Food and Drug Administration. FDA approves lisocabtagene maraleucel for relapsed or refractory marginal zone lymphoma. Accessed: June 30, 2026. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-marginal-zone-lymphoma

Ref. 728. Palomba ML, et al. (2026) Lancet, 407: 963. Available from: https://doi.org/10.1016/S0140-6736(25)02435-3

Ref. 729. Brudno JN, et al. (2024) JAMA, 332: 1924. Available from: https://doi.org/10.1001/jama.2024.19462

Ref. 730. Rejeski K, et al. (2025) Nat Med, 31: 2132. Available from: https://doi.org/10.1038/s41591-025-03813-5

Ref. 731. Chen GM, et al. (2026) Nat Biomed Eng, 10: 803. Available from: https://doi.org/10.1038/s41551-026-01633-7

Ref. 732. Mulvey A, et al. (2025) Nat Rev Drug Discov, 24: 379. Available from: https://doi.org/10.1038/s41573-024-01100-5

Ref. 733. Scheller L, et al. (2026) Nat Chem Biol. Available from: https://doi.org/10.1038/s41589-026-02152-x

Ref. 734. Vunjak-Novakovic G (2026) Nat Biotechnol, 44: 907. Available from: https://doi.org/10.1038/s41587-025-02819-1

Ref. 735. Binder ZA, et al. (2026) Nat Rev Clin Oncol, 23: 137. Available from: https://doi.org/10.1038/s41571-025-01102-1

Ref. 736. Tsahouridis O, et al. (2025) Nat Cancer, 6: 1145. Available from: https://doi.org/10.1038/s43018-025-01015-z

Ref. 737. Reiss KA, et al. (2025) Nat Med, 31: 1171. Available from: https://doi.org/10.1038/s41591-025-03495-z

Ref. 738. Rouce RH (2025) Nat Rev Immunol, 25: 777. Available from: https://doi.org/10.1038/s41577-025-01228-4

Ref. 739. Baselga J, et al. (2015) Clin Cancer Res, 21: S1. Available from: https://doi.org/10.1158/1078-0432.CCR-15-1846

Ref. 740. Tian Z, et al. (2021) J Hematol Oncol, 14: 75. Available from: https://doi.org/10.1186/s13045-021-01084-4

Ref. 741. US Food and Drug Administration. FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or refractory multiple myeloma. Accessed: June 30, 2026. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-linvoseltamab-gcpt-relapsed-or-refractory-multiple-myeloma

Ref. 742. Bumma N, et al. (2024) J Clin Oncol, 42: 2702. Available from: https://doi.org/10.1200/JCO.24.01008

Ref. 743. Rolin C, et al. (2024) Cell Mol Immunol, 21: 643. Available from: https://doi.org/10.1038/s41423-024-01176-4

Ref. 744. Hevroni G, et al. (2024) Blood Rev, 68: 101242. Available from: https://doi.org/10.1016/j.blre.2024.101242

Ref. 745. Cordas Dos Santos DM, et al. (2024) Nat Rev Cancer, 24: 867. Available from: https://doi.org/10.1038/s41568-024-00755-x

Ref. 746. Kyle RA, et al. (2018) N Engl J Med, 378: 241. Available from: https://doi.org/10.1056/NEJMoa1709974

Ref. 747. Murray D, et al. (2019) Blood Cancer J, 9: 102. Available from: https://doi.org/10.1038/s41408-019-0263-z

Ref. 748. Dimopoulos MA, et al. (2025) N Engl J Med, 392: 1777. Available from: https://doi.org/10.1056/NEJMoa2409029

Ref. 749. Mollica MA, et al. (2025) Cancer, 131: e70039. Available from: https://doi.org/10.1002/cncr.70039

Ref. 750. Centers for Disease Control and Prevention. (2004) MMWR Morb Mortal Wkly Rep, 53: 526

Ref. 751. Gallicchio L, et al. (2026) Cancer Epidemiol Biomarkers Prev, 35: 321. Available from: https://doi.org/10.1158/1055-9965.EPI-25-1196

Ref. 752. Li Q, et al. (2025) EClinicalMedicine, 84: 103274. Available from: https://doi.org/10.1016/j.eclinm.2025.103274

Ref. 753. Strongman H, et al. (2022) JACC CardioOncol, 4: 113. Available from: https://doi.org/10.1016/j.jaccao.2022.01.102

Ref. 754. Herrmann J (2020) Nat Rev Cardiol, 17: 474. Available from: https://doi.org/10.1038/s41569-020-0348-1

Ref. 755. Shyr D, et al. (2026) JAMA Oncol, 12: 251. Available from: https://doi.org/10.1001/jamaoncol.2025.5785

Ref. 756. Barac A, et al. (2025) JAMA Oncol, 11: 1479. Available from: https://doi.org/10.1001/jamaoncol.2025.4178

Ref. 757. Shah I, et al. (2026) Radiother Oncol, 218: 111455. Available from: https://doi.org/10.1016/j.radonc.2026.111455

Ref. 758. Karschnia P, et al. (2025) Nat Rev Cancer, 25: 887. Available from: https://doi.org/10.1038/s41568-025-00863-2

Ref. 759. Seretny M, et al. (2014) Pain, 155: 2461. Available from: https://doi.org/10.1016/j.pain.2014.09.020

Ref. 760. Jordan B, et al. (2020) Ann Oncol, 31: 1306. Available from: https://doi.org/10.1016/j.annonc.2020.07.003

Ref. 761. Loprinzi CL, et al. (2020) J Clin Oncol, 38: 3325. Available from: https://doi.org/10.1200/JCO.20.01399

Ref. 762. Hanvic B, et al. (2025) Eur J Cancer, 229: 115791. Available from: https://doi.org/10.1016/j.ejca.2025.115791

Ref. 763. Michel LL, et al. (2025) JAMA Oncol, 11: 408. Available from: https://doi.org/10.1001/jamaoncol.2025.0001

Ref. 764. Servitja S, et al. (2026) Clin Transl Oncol, 28: 1040. Available from: https://doi.org/10.1007/s12094-025-04062-1

Ref. 765. Argiles JM, et al. (2014) Nat Rev Cancer, 14: 754. Available from: https://doi.org/10.1038/nrc3829

Ref. 766. Tan Y, et al. (2026) Signal Transduct Target Ther, 11: 16. Available from: https://doi.org/10.1038/s41392-025-02331-7

Ref. 767. Koh K, et al. (2025) Cancer Discov, 15: 1543. Available from: https://doi.org/10.1158/2159-8290.CD-25-0293

Ref. 768. Groarke JD, et al. (2024) N Engl J Med, 391: 2291. Available from: https://doi.org/10.1056/NEJMoa2409515

Ref. 769. Mullard A (2025) Nat Rev Drug Discov, 24: 811. Available from: https://doi.org/10.1038/d41573-025-00168-x

Ref. 770. Garrett A, et al. (2025) Cell, 188: 6044. Available from: https://doi.org/10.1016/j.cell.2025.07.016

Ref. 771. Zhang Y, et al. (2026) Cancer Cell, 44: 913. Available from: https://doi.org/10.1016/j.ccell.2026.03.012

Ref. 772. Bhatt BJ, et al. (2025) Nature, 646: 973. Available from: https://doi.org/10.1038/s41586-025-09502-0

Ref. 773. Zhu XA, et al. (2025) Science, 388: eadm8857. Available from: https://doi.org/10.1126/science.adm8857

Ref. 774. Pu J, et al. (2026) Cancer Epidemiol Biomarkers Prev. Available from: https://doi.org/10.1158/1055-9965.EPI-26-0096

Ref. 775. Feng Y, et al. (2026) Support Care Cancer, 34. Available from: https://doi.org/10.1007/s00520-026-10643-9

Ref. 776. Mevawalla A, et al. (2026) J Cancer Surviv. Available from: https://doi.org/10.1007/s11764-026-01981-y

Ref. 777. Zeng M, et al. (2025) J Transl Med, 23: 115. Available from: https://doi.org/10.1186/s12967-025-06151-9

Ref. 778. Wang Y, et al. (2025) J Transl Med, 23: 355. Available from: https://doi.org/10.1186/s12967-025-06379-5

Ref. 779. Cheng HG, et al. (2026) Cancer Med, 15: e71778. Available from: https://doi.org/10.1002/cam4.71778

Ref. 780. Penberthy L, et al. (2024) J Natl Cancer Inst Monogr, 2024: 110. Available from: https://doi.org/10.1093/jncimonographs/lgae022

Ref. 781. Thompson TD, et al. (2020) Cancer Epidemiol, 64: 101653. Available from: https://doi.org/10.1016/j.canep.2019.101653

Ref. 782. Brunson A, et al. (2026) JAMA Oncol, 12: 75. Available from: https://doi.org/10.1001/jamaoncol.2025.4971

Ref. 783. Hsu E, et al. (2024) J Natl Cancer Inst Monogr, 2024: 145. Available from: https://doi.org/10.1093/jncimonographs/lgae018

Ref. 784. Adashek JJ, et al. (2025) Cancer Metastasis Rev, 44: 43. Available from: https://doi.org/10.1007/s10555-025-10260-8

Ref. 785. Johnson DB, et al. (2022) Nat Rev Clin Oncol, 19: 254. Available from: https://doi.org/10.1038/s41571-022-00600-w

Ref. 786. Jayathilaka B, et al. (2025) Br J Cancer, 132: 51. Available from: https://doi.org/10.1038/s41416-024-02887-1

Ref. 787. Abraham PE, et al. (2025) Drugs, 85: 1535. Available from: https://doi.org/10.1007/s40265-025-02243-4

Ref. 788. Zhu Y, et al. (2025) EClinicalMedicine, 84: 103267. Available from: https://doi.org/10.1016/j.eclinm.2025.103267

Ref. 789. Camacho-Arteaga L, et al. (2025) JAMA Netw Open, 8: e2461683. Available from: https://doi.org/10.1001/jamanetworkopen.2024.61683

Ref. 790. Tan HN, et al. (2025) J Hematol Oncol, 18: 71. Available from: https://doi.org/10.1186/s13045-025-01720-3

Ref. 791. LeVee A, et al. (2025) Am Soc Clin Oncol Educ Book, 45: e473384. Available from: https://doi.org/10.1200/EDBK-25-473384

Ref. 792. US Food and Drug Administration. FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients. Accessed: June 30, 2026. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-uses-donor-immune-cells-prevent-serious-complications-blood-cancer

Ref. 793. Ge MW, et al. (2025) Psychooncology, 34: e70077. Available from: https://doi.org/10.1002/pon.70077

Ref. 794. Kim I, et al. (2025) BMJ Open, 15: e090157. Available from: https://doi.org/10.1136/bmjopen-2024-090157

Ref. 795. Ganjouei AA, et al. (2026) Cancer, 132: e70254. Available from: https://doi.org/10.1002/cncr.70254

Ref. 796. Wheldon CW, et al. (2025) Sci Rep, 15: 3914. Available from: https://doi.org/10.1038/s41598-025-85126-8

Ref. 797. Lee H, et al. (2026) Qual Life Res, 35: 44. Available from: https://doi.org/10.1007/s11136-025-04159-8

Ref. 798. Cheng S, et al. (2025) BMJ Oncol, 4: e000840. Available from: https://doi.org/10.1136/bmjonc-2025-000840

Ref. 799. Bogner S, et al. (2025) EClinicalMedicine, 90: 103670. Available from: https://doi.org/10.1016/j.eclinm.2025.103670

Ref. 800. Martinez-Calderon J, et al. (2025) Cancers (Basel), 17. Available from: https://doi.org/10.3390/cancers17111788

Ref. 801. Han X, et al. (2021) J Natl Cancer Inst, 113: 1258. Available from: https://doi.org/10.1093/jnci/djaa183

Ref. 802. Liu Q, et al. (2024) Transl Psychiatry, 14: 213. Available from: https://doi.org/10.1038/s41398-024-02917-9

Ref. 803. Matsuo K, et al. (2024) JAMA Netw Open, 7: e2442964. Available from: https://doi.org/10.1001/jamanetworkopen.2024.42964

Ref. 804. Wang S, et al. (2024) Eur J Oncol Nurs, 68: 102489. Available from: https://doi.org/10.1016/j.ejon.2023.102489

Ref. 805. Rose L, et al. (2025) JAMA Netw Open, 8: e2521575. Available from: https://doi.org/10.1001/jamanetworkopen.2025.21575

Ref. 806. Barnes JM, et al. (2026) JAMA Netw Open, 9: e2556451. Available from: https://doi.org/10.1001/jamanetworkopen.2025.56451

Ref. 807. Dhir A, et al. (2024) JAMA Netw Open, 7: e2429286. Available from: https://doi.org/10.1001/jamanetworkopen.2024.29286

Ref. 808. Yabroff KR, et al. (2024) CA Cancer J Clin, 74: 341. Available from: https://doi.org/10.3322/caac.21837

Ref. 809. Han X, et al. (2020) Cancer Epidemiol Biomarkers Prev, 29: 308. Available from: https://doi.org/10.1158/1055-9965.EPI-19-0460

Ref. 810. Mollica MA, et al. (2024) Support Care Cancer, 32: 137. Available from: https://doi.org/10.1007/s00520-024-08328-2

Ref. 811. Uppal N, et al. (2025) JAMA Oncol, 11: 1321. Available from: https://doi.org/10.1001/jamaoncol.2025.3302

Ref. 812. Yabroff KR, et al. (2016) J Clin Oncol, 34: 259. Available from: https://doi.org/10.1200/JCO.2015.62.0468

Ref. 813. Chen M, et al. (2026) J Cancer Surviv. Available from: https://doi.org/10.1007/s11764-026-02010-8

Ref. 814. Williams CP, et al. (2026) JCO Oncol Pract: OP2500683. Available from: https://doi.org/10.1200/OP-25-00683

Ref. 815. Zheng Z, et al. (2024) Cancer, 130: 2938. Available from: https://doi.org/10.1002/cncr.35342

Ref. 816. Angez M, et al. (2026) J Cancer Surviv. Available from: https://doi.org/10.1007/s11764-026-02004-6

Ref. 817. Mengesha SZ, et al. (2026) Cancer Res Commun, 6: 803. Available from: https://doi.org/10.1158/2767-9764.CRC-25-0344

Ref. 818. Xing J, et al. (2026) JCO Oncol Pract, 22: 159. Available from: https://doi.org/10.1200/OP-25-00045

Ref. 819. Nguyen TD, et al. (2025) Cancer Med, 14: e71436. Available from: https://doi.org/10.1002/cam4.71436

Ref. 820. Banegas MP, et al. (2025) JCO Oncol Pract, 21: 1512. Available from: https://doi.org/10.1200/OP-24-00902

Ref. 821. De Moor JS, et al. (2026) J Natl Cancer Inst. Available from: https://doi.org/10.1093/jnci/djag077

Ref. 822. Chen KL, et al. (2025) JAMA Netw Open, 8: e2528976. Available from: https://doi.org/10.1001/jamanetworkopen.2025.28976

Ref. 823. Kohut-Jackson A, et al. (2026) JCO Oncol Pract: OP2600261. Available from: https://doi.org/10.1200/OP-26-00261

Ref. 824. Siegel RL, et al. (2025) CA Cancer J Clin, 75: 10. Available from: https://doi.org/10.3322/caac.21871

Ref. 825. Ehrhardt MJ, et al. (2023) Nat Rev Clin Oncol, 20: 678. Available from: https://doi.org/10.1038/s41571-023-00802-w

Ref. 826. Meijer AJM, et al. (2022) Cancer, 128: 169. Available from: https://doi.org/10.1002/cncr.33848

Ref. 827. Brock PR, et al. (2018) N Engl J Med, 378: 2376. Available from: https://doi.org/10.1056/NEJMoa1801109

Ref. 828. Ohlsen TJD, et al. (2025) Pediatr Blood Cancer, 72: e31479. Available from: https://doi.org/10.1002/pbc.31479

Ref. 829. Bhatia S, et al. (2023) JAMA, 330: 1175. Available from: https://doi.org/10.1001/jama.2023.16875

Ref. 830. Ryan TD, et al. (2025) Circulation, 151: e926. Available from: https://doi.org/10.1161/CIR.0000000000001308

Ref. 831. Lim HM, et al. (2025) Curr Treat Options Oncol, 27: 1. Available from: https://doi.org/10.1007/s11864-025-01367-9

Ref. 832. Bowers DC, et al. (2025) JAMA Netw Open, 8: e2548715. Available from: https://doi.org/10.1001/jamanetworkopen.2025.48715

Ref. 833. Galvin RT, et al. (2025) J Natl Cancer Inst, 117: 1036. Available from: https://doi.org/10.1093/jnci/djaf005

Ref. 834. Owens CA, et al. (2025) J Clin Oncol, 43: 3403. Available from: https://doi.org/10.1200/JCO-25-00531

Ref. 835. Shah R, et al. (2026) Cancer Imaging, 26. Available from: https://doi.org/10.1186/s40644-025-00933-6

Ref. 836. Neupane A, et al. (2025) JAMA Netw Open, 8: e2515793. Available from: https://doi.org/10.1001/jamanetworkopen.2025.15793

Ref. 837. Wang Z, et al. (2025) Nat Rev Cancer, 25: 129. Available from: https://doi.org/10.1038/s41568-024-00768-6

Ref. 838. Bhakta N, et al. (2017) Lancet, 390: 2569. Available from: https://doi.org/10.1016/S0140-6736(17)31610-0

Ref. 839. Phillips SM, et al. (2015) Cancer Epidemiol Biomarkers Prev, 24: 653. Available from: https://doi.org/10.1158/1055-9965.EPI-14-1418

Ref. 840. Yeh JM, et al. (2025) JAMA Oncol, 11: 535. Available from: https://doi.org/10.1001/jamaoncol.2025.0236

Ref. 841. Bhandari R, et al. (2025) J Clin Oncol, 43: 2998. Available from: https://doi.org/10.1200/JCO-25-00385

Ref. 842. Kim Y, et al. (2025) Pediatr Blood Cancer, 72: e31980. Available from: https://doi.org/10.1002/pbc.31980

Ref. 843. Patel T, et al. (2025) Front Neurosci, 19: 1587059. Available from: https://doi.org/10.3389/fnins.2025.1587059

Ref. 844. Jacola LM, et al. (2025) J Clin Exp Neuropsychol, 47: 788. Available from: https://doi.org/10.1080/13803395.2025.2521018

Ref. 845. Zheng DJ, et al. (2026) J Natl Cancer Inst. Available from: https://doi.org/10.1093/jnci/djaf383

Ref. 846. Williams AM, et al. (2025) Nat Commun, 16: 10655. Available from: https://doi.org/10.1038/s41467-025-65664-5

Ref. 847. Phillips NS, et al. (2025) JAMA Netw Open, 8: e2551865. Available from: https://doi.org/10.1001/jamanetworkopen.2025.51865

Ref. 848. Yardeni M, et al. (2025) Pediatr Res. Available from: https://doi.org/10.1038/s41390-025-04724-4

Ref. 849. Maas A, et al. (2025) Psychooncology, 34: e70101. Available from: https://doi.org/10.1002/pon.70101

Ref. 850. The Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Among Adolescents and Young Adults (AYAs) – Cancer Stat Facts. Accessed: June 30, 2026. Available from: https://seer.cancer.gov/statfacts/html/aya.html

Ref. 851. Bergerot C, et al. (2026) Am Soc Clin Oncol Educ Book, 46: e520636. Available from: https://doi.org/10.1200/EDBK-26-520636

Ref. 852. Berkman AM, et al. (2024) J Natl Cancer Inst, 116: 1417. Available from: https://doi.org/10.1093/jnci/djae119

Ref. 853. Freyer DR, et al. (2026) J Cancer Surviv. Available from: https://doi.org/10.1007/s11764-026-01986-7

Ref. 854. Keegan THM, et al. (2025) Cancer, 131: e70125. Available from: https://doi.org/10.1002/cncr.70125

Ref. 855. van der Meer DJ, et al. (2024) Oncologist, 29: e526. Available from: https://doi.org/10.1093/oncolo/oyad307

Ref. 856. Sung H, et al. (2022) J Natl Cancer Inst, 114: 1095. Available from: https://doi.org/10.1093/jnci/djac091

Ref. 857. Su HI, et al. (2025) J Clin Oncol, 43: 1488. Available from: https://doi.org/10.1200/JCO-24-02782

Ref. 858. Talbot L, et al. (2025) Pediatr Blood Cancer, 72 Suppl 2: e31277. Available from: https://doi.org/10.1002/pbc.31277

Ref. 859. Castillo J, et al. (2026) JAMA, 335: 1169. Available from: https://doi.org/10.1001/jama.2026.0070

Ref. 860. Mobley EM, et al. (2026) JCO Oncol Pract, 22: 112. Available from: https://doi.org/10.1200/OP-24-01017

Ref. 861. Alliance for Fertility Preservation. State Laws & Legislation. Accessed: June 30, 2026. Available from: https://www.allianceforfertilitypreservation.org/expenses/laws-legislation/

Ref. 862. McGrady ME, et al. (2024) J Clin Oncol, 42: 707. Available from: https://doi.org/10.1200/JCO.23.01465

Ref. 863. Chen Z, et al. (2025) J Cancer Surviv. Available from: https://doi.org/10.1007/s11764-025-01812-6

Ref. 864. Storandt MH, et al. (2025) JAMA Netw Open, 8: e2527421. Available from: https://doi.org/10.1001/jamanetworkopen.2025.27421

Ref. 865. Zhang A, et al. (2025) JAMA Netw Open, 8: e2511430. Available from: https://doi.org/10.1001/jamanetworkopen.2025.11430

Ref. 866. Das A, et al. (2025) Cancer Med, 14: e71247. Available from: https://doi.org/10.1002/cam4.71247

Ref. 867. Ghazal LV, et al. (2026) J Cancer Surviv. Available from: https://doi.org/10.1007/s11764-026-01991-w

Ref. 868. Kirchhoff AC, et al. (2024) J Clin Oncol, 42: 642. Available from: https://doi.org/10.1200/JCO.23.01027

Ref. 869. Thom B, et al. (2023) J Cancer Surviv, 17: 1813. Available from: https://doi.org/10.1007/s11764-022-01280-2

Ref. 870. Bhurosy T, et al. (2026) BMC Cancer, 26. Available from: https://doi.org/10.1186/s12885-026-15751-7

Ref. 871. Robles JM, et al. (2025) JCO Oncol Pract: OP2500389. Available from: https://doi.org/10.1200/OP-25-00389

Ref. 872. Ehrhardt MJ, et al. (2024) J Clin Oncol, 42: 743. Available from: https://doi.org/10.1200/JCO.23.01504

Ref. 873. Wong CL, et al. (2024) BMJ Open, 14: e087343. Available from: https://doi.org/10.1136/bmjopen-2024-087343

Ref. 874. DeVine A, et al. (2025) JAMA Oncol, 11: 544. Available from: https://doi.org/10.1001/jamaoncol.2024.6812

Ref. 875. Hudson MM, et al. (2021) Pediatrics, 148. Available from: https://doi.org/10.1542/peds.2021-053127

Ref. 876. de Beijer IAE, et al. (2025) BMC Health Serv Res, 25: 1331. Available from: https://doi.org/10.1186/s12913-025-13363-8

Ref. 877. Milam J, et al. (2024) Pediatr Blood Cancer, 71: e31328. Available from: https://doi.org/10.1002/pbc.31328

Ref. 878. Bluethmann SM, et al. (2016) Cancer Epidemiol Biomarkers Prev, 25: 1029. Available from: https://doi.org/10.1158/1055-9965.EPI-16-0133

Ref. 879. Miller KD, et al. (2022) CA Cancer J Clin, 72: 409. Available from: https://doi.org/10.3322/caac.21731

Ref. 880. Williams GR, et al. (2018) Oncologist, 23: 433. Available from: https://doi.org/10.1634/theoncologist.2017-0404

Ref. 881. Duchesneau ED, et al. (2025) JAMA Netw Open, 8: e250614. Available from: https://doi.org/10.1001/jamanetworkopen.2025.0614

Ref. 882. Han CJ, et al. (2024) Qual Life Res, 33: 583. Available from: https://doi.org/10.1007/s11136-023-03537-4

Ref. 883. Sedrak MS, et al. (2024) J Cancer Surviv, 18: 1131. Available from: https://doi.org/10.1007/s11764-024-01594-3

Ref. 884. La J, et al. (2025) J Natl Compr Canc Netw, 23: 363. Available from: https://doi.org/10.6004/jnccn.2025.7051

Ref. 885. Mohamed MR, et al. (2024) Support Care Cancer, 32: 674. Available from: https://doi.org/10.1007/s00520-024-08877-6

Ref. 886. Taher ASM, et al. (2026) Curr Oncol Rep, 28. Available from: https://doi.org/10.1007/s11912-026-01780-9

Ref. 887. Gupta A, et al. (2025) JAMA Netw Open, 8: e2547924. Available from: https://doi.org/10.1001/jamanetworkopen.2025.47924

Ref. 888. Pu J, et al. (2025) J Cancer Surviv, 19: 1255. Available from: https://doi.org/10.1007/s11764-024-01549-8

Ref. 889. Taylor M, et al. (2025) JAMA Netw Open, 8: e2544812. Available from: https://doi.org/10.1001/jamanetworkopen.2025.44812

Ref. 890. Pilleron S, et al. (2023) J Geriatr Oncol, 14: 101519. Available from: https://doi.org/10.1016/j.jgo.2023.101519

Ref. 891. Zhao J, et al. (2024) J Natl Compr Canc Netw, 22: 244. Available from: https://doi.org/10.6004/jnccn.2023.7114

Ref. 892. Kadambi S, et al. (2025) JCO Oncol Pract, 21: 92. Available from: https://doi.org/10.1200/OP.24.00105

Ref. 893. Myers S, et al. (2025) Support Care Cancer, 33: 339. Available from: https://doi.org/10.1007/s00520-025-09393-x

Ref. 894. Owsley KM, et al. (2025) J Cancer Surviv. Available from: https://doi.org/10.1007/s11764-025-01797-2

Ref. 895. Pak TY (2025) Health Econ Rev, 15: 22. Available from: https://doi.org/10.1186/s13561-025-00596-w

Ref. 896. Bergerot CD, et al. (2025) JCO Glob Oncol, 11: e2500276. Available from: https://doi.org/10.1200/GO-25-00276

Ref. 897. Magnuson A, et al. (2024) CA Cancer J Clin, 74: 496. Available from: https://doi.org/10.3322/caac.21864

Ref. 898. Ginex PK, et al. (2026) Support Care Cancer, 34: 125. Available from: https://doi.org/10.1007/s00520-026-10367-w

Ref. 899. Hundal J, et al. (2026) Am Soc Clin Oncol Educ Book, 46: e517396. Available from: https://doi.org/10.1200/EDBK-26-517396

Ref. 900. Rees-Punia E, et al. (2026) JAMA Netw Open, 9: e2556971. Available from: https://doi.org/10.1001/jamanetworkopen.2025.56971

Ref. 901. Wilson OWA, et al. (2025) Cancer Epidemiol Biomarkers Prev, 34: 1252. Available from: https://doi.org/10.1158/1055-9965.EPI-24-1798

Ref. 902. Chen X, et al. (2025) Int J Surg, 111: 3373. Available from: https://doi.org/10.1097/JS9.0000000000002323

Ref. 903. Courneya KS, et al. (2025) N Engl J Med, 393: 13. Available from: https://doi.org/10.1056/NEJMoa2502760

Ref. 904. Rayner CJ, et al. (2025) J Sport Health Sci, 14: 101063. Available from: https://doi.org/10.1016/j.jshs.2025.101063

Ref. 905. Joffe L, et al. (2025) JAMA Oncol, 11: 835. Available from: https://doi.org/10.1001/jamaoncol.2025.1340

Ref. 906. Mayr AK, et al. (2025) Cancer, 131: e70051. Available from: https://doi.org/10.1002/cncr.70051

Ref. 907. Ulrich CM, et al. (2025) JAMA Surg, 160: 495. Available from: https://doi.org/10.1001/jamasurg.2025.0130

Ref. 908. Galvao DA, et al. (2025) JAMA Netw Open, 8: e250413. Available from: https://doi.org/10.1001/jamanetworkopen.2025.0413

Ref. 909. Soong RY, et al. (2025) JAMA Netw Open, 8: e2457859. Available from: https://doi.org/10.1001/jamanetworkopen.2024.57859

Ref. 910. Wang Y, et al. (2025) J Natl Cancer Inst, 117: 1260. Available from: https://doi.org/10.1093/jnci/djaf051

Ref. 911. Lee CT, et al. (2026) Cancer Epidemiol Biomarkers Prev, 35: 379. Available from: https://doi.org/10.1158/1055-9965.EPI-25-1470

Ref. 912. Lan T, et al. (2026) Cancer, 132: e70246. Available from: https://doi.org/10.1002/cncr.70246

Ref. 913. Bhatt NS, et al. (2026) JAMA Netw Open, 9: e2615527. Available from: https://doi.org/10.1001/jamanetworkopen.2026.15527

Ref. 914. Kaur H, et al. (2025) J Natl Compr Canc Netw, 23. Available from: https://doi.org/10.6004/jnccn.2025.7012

Ref. 915. Lin JC, et al. (2025) JAMA Health Forum, 6: e251381. Available from: https://doi.org/10.1001/jamahealthforum.2025.1381

Ref. 916. Aziz-Bose R, et al. (2026) Support Care Cancer, 34. Available from: https://doi.org/10.1007/s00520-026-10870-0

Ref. 917. Ligibel JA, et al. (2025) JAMA Oncol, 11: 1194. Available from: https://doi.org/10.1001/jamaoncol.2025.2738

Ref. 918. Sukumar JS, et al. (2026) Cancer Res Commun, 6: 447. Available from: https://doi.org/10.1158/2767-9764.CRC-25-0554

Ref. 919. Tatum KL, et al. (2026) JAMA Netw Open, 9: e2612133. Available from: https://doi.org/10.1001/jamanetworkopen.2026.12133

Ref. 920. Javaid SS, et al. (2026) Am J Cardiol, 273: 59. Available from: https://doi.org/10.1016/j.amjcard.2026.06.008

Ref. 921. Caturegli G, et al. (2025) JAMA Oncol, 11: 564. Available from: https://doi.org/10.1001/jamaoncol.2025.0247

Ref. 922. Parsons HM, et al. (2020) JAMA Oncol, 6: 923. Available from: https://doi.org/10.1001/jamaoncol.2020.0384

Ref. 923. Lopez-Olivo MA, et al. (2024) J Cancer Surviv, 18: 1059. Available from: https://doi.org/10.1007/s11764-023-01357-6

Ref. 924. Wong C, et al. (2025) JAMA Netw Open, 8: e250295. Available from: https://doi.org/10.1001/jamanetworkopen.2025.0295

Ref. 925. Lorona NC, et al. (2024) Cancer Epidemiol Biomarkers Prev, 33: 288. Available from: https://doi.org/10.1158/1055-9965.EPI-23-1081

Ref. 926. Borgert B, et al. (2026) Cancer, 132: e70336. Available from: https://doi.org/10.1002/cncr.70336

Ref. 927. An Z, et al. (2025) J Cancer Surviv. Available from: https://doi.org/10.1007/s11764-025-01959-2

Ref. 928. Caini S, et al. (2025) Tob Control. Available from: https://doi.org/10.1136/tc-2024-058873

Ref. 929. Li L, et al. (2026) Cancer Causes Control, 37. Available from: https://doi.org/10.1007/s10552-026-02153-0

Ref. 930. Tohmasi S, et al. (2025) J Natl Compr Canc Netw, 23. Available from: https://doi.org/10.6004/jnccn.2025.7059

Ref. 931. Liu X, et al. (2026) JAMA Netw Open, 9: e261543. Available from: https://doi.org/10.1001/jamanetworkopen.2026.1543

Ref. 932. Kiefer P, et al. (2025) Sci Rep, 15: 20137. Available from: https://doi.org/10.1038/s41598-025-04849-w

Ref. 933. Lai JH, et al. (2025) J Intern Med, 298: 670. Available from: https://doi.org/10.1111/joim.70033

Ref. 934. Gapstur SM, et al. (2022) Cancer Epidemiol Biomarkers Prev, 31: 5. Available from: https://doi.org/10.1158/1055-9965.EPI-21-0934

Ref. 935. Avancena ALV, et al. (2025) J Natl Compr Canc Netw, 23: 156. Available from: https://doi.org/10.6004/jnccn.2025.7007

Ref. 936. Heffner JL, et al. (2024) Cancer Epidemiol Biomarkers Prev, 33: 600. Available from: https://doi.org/10.1158/1055-9965.EPI-23-1155

Ref. 937. Bai XL, et al. (2025) Br J Sports Med, 59: 1010. Available from: https://doi.org/10.1136/bjsports-2024-109392

Ref. 938. Fu W, et al. (2025) Transl Psychiatry, 15: 327. Available from: https://doi.org/10.1038/s41398-025-03507-z

Ref. 939. Bergerot C, et al. (2024) EClinicalMedicine, 78: 102942. Available from: https://doi.org/10.1016/j.eclinm.2024.102942

Ref. 940. Cheville AL, et al. (2026) Lancet Oncol, 27: 125. Available from: https://doi.org/10.1016/S1470-2045(25)00526-1

Ref. 941. Li M, et al. (2017) Psychooncology, 26: 573. Available from: https://doi.org/10.1002/pon.4286

Ref. 942. Abdalla T, et al. (2026) J Natl Cancer Inst, 118: 26. Available from: https://doi.org/10.1093/jnci/djaf153

Ref. 943. Smith A, et al. (2026) J Cancer Surviv, 20: 766. Available from: https://doi.org/10.1007/s11764-024-01685-1

Ref. 944. Graboyes EM, et al. (2025) Psychooncology, 34: e70309. Available from: https://doi.org/10.1002/pon.70309

Ref. 945. Salsman JM, et al. (2024) Cancer, 130: 1031. Available from: https://doi.org/10.1002/cncr.35182

Ref. 946. Caldiroli CL, et al. (2025) Sci Rep, 15: 8599. Available from: https://doi.org/10.1038/s41598-025-93008-2

Ref. 947. Rosenberg AR, et al. (2021) JAMA Netw Open, 4: e2136039. Available from: https://doi.org/10.1001/jamanetworkopen.2021.36039

Ref. 948. Rosenberg AR, et al. (2026) JCO Oncol Pract, 22: 243. Available from: https://doi.org/10.1200/OP-25-00161

Ref. 949. Devine KA, et al. (2026) JAMA Netw Open, 9: e267997. Available from: https://doi.org/10.1001/jamanetworkopen.2026.7997

Ref. 950. Wardill HR, et al. (2026) JCO Glob Oncol, 12: e2600087. Available from: https://doi.org/10.1200/GO-26-00087

Ref. 951. Currow DC, et al. (2020) J Clin Oncol, 38: 937. Available from: https://doi.org/10.1200/JCO.18.02235

Ref. 952. Taylor A, et al. (2025) Clin Med (Lond), 25: 100487. Available from: https://doi.org/10.1016/j.clinme.2025.100487

Ref. 953. Creanga-Murariu I, et al. (2025) Cancers (Basel), 17. Available from: https://doi.org/10.3390/cancers17152598

Ref. 954. Haroen H, et al. (2025) BMC Palliat Care, 24: 120. Available from: https://doi.org/10.1186/s12904-025-01737-y

Ref. 955. Petrillo LA, et al. (2024) Am Soc Clin Oncol Educ Book, 44: e100038. Available from: https://doi.org/10.1200/EDBK_100038

Ref. 956. Hart NH, et al. (2024) JCO Oncol Pract, 20: 1160. Available from: https://doi.org/10.1200/OP.23.00716

Ref. 957. Jefford M, et al. (2025) Am Soc Clin Oncol Educ Book, 45: e471752. Available from: https://doi.org/10.1200/EDBK-25-471752

Ref. 958. Mollica MA, et al. (2026) Cancer Epidemiol Biomarkers Prev, 35: 692. Available from: https://doi.org/10.1158/1055-9965.EPI-25-1721

Ref. 959. Sanders JJ, et al. (2024) J Clin Oncol, 42: 2336. Available from: https://doi.org/10.1200/JCO.24.00542

Ref. 960. Richardson DR, et al. (2026) JAMA Oncol, 12: 517. Available from: https://doi.org/10.1001/jamaoncol.2026.0072

Ref. 961. Shah MP, et al. (2025) Cancer, 131: e35976. Available from: https://doi.org/10.1002/cncr.35976

Ref. 962. Kwon Y, et al. (2025) JAMA Health Forum, 6: e245436. Available from: https://doi.org/10.1001/jamahealthforum.2024.5436

Ref. 963. Temel JS, et al. (2024) JAMA, 332: 471. Available from: https://doi.org/10.1001/jama.2024.10398

Ref. 964. Kawashima A, et al. (2026) Palliat Med, 40: 588. Available from: https://doi.org/10.1177/02692163251403395

Ref. 965. Ver Hoeve ES, et al. (2024) BMC Health Serv Res, 24: 550. Available from: https://doi.org/10.1186/s12913-024-10919-y

Ref. 966. Gany F, et al. (2025) J Natl Compr Canc Netw: 1. Available from: https://doi.org/10.6004/jnccn.2025.7017

Ref. 967. Oluwole SF, et al. (2003) J Am Coll Surg, 196: 180. Available from: https://doi.org/10.1016/s1072-7515(02)01765-9

Ref. 968. Chan RJ, et al. (2023) CA Cancer J Clin, 73: 565. Available from: https://doi.org/10.3322/caac.21788

Ref. 969. Causey L, et al. (2025) Clin J Oncol Nurs, 29: E60. Available from: https://doi.org/10.1188/25.CJON.E60-E69

Ref. 970. Hong M, et al. (2024) Neurooncol Pract, 11: 575. Available from: https://doi.org/10.1093/nop/npae030

Ref. 971. Edward J, et al. (2024) JNCI Cancer Spectr, 8. Available from: https://doi.org/10.1093/jncics/pkae025

Ref. 972. Wheeler SB, et al. (2024) J Natl Compr Canc Netw, 22: 557. Available from: https://doi.org/10.6004/jnccn.2024.7030

Ref. 973. Dobbs JE, et al. (2025) JAMA Oncol, 11: 235. Available from: https://doi.org/10.1001/jamaoncol.2024.6270

Ref. 974. Yan AP, et al. (2020) J Clin Oncol, 38: 1711. Available from: https://doi.org/10.1200/JCO.19.01825

Ref. 975. Tsai MH, et al. (2024) J Cancer Surviv, 18: 781. Available from: https://doi.org/10.1007/s11764-022-01309-6

Ref. 976. Santos-Teles M, et al. (2024) Support Care Cancer, 32: 798. Available from: https://doi.org/10.1007/s00520-024-08986-2

Ref. 977. Tarver WL, et al. (2025) J Cancer Surviv, 19: 1956. Available from: https://doi.org/10.1007/s11764-024-01609-z

Ref. 978. Ji X, et al. (2026) J Natl Cancer Inst, 118: 85. Available from: https://doi.org/10.1093/jnci/djaf276

Ref. 979. Singh AP, et al. (2025) JCO Oncol Pract, 21: 128. Available from: https://doi.org/10.1200/OP.24.00260

Ref. 980. Atlas SJ, et al. (2025) JCO Oncol Pract, 21: 123. Available from: https://doi.org/10.1200/OP.23.00818

Ref. 981. Birken SA, et al. (2025) JCO Oncol Pract, 21: 766. Available from: https://doi.org/10.1200/OP.23.00699

Ref. 982. Balasubramanian BA, et al. (2026) JCO Oncol Pract: OP2501275. Available from: https://doi.org/10.1200/OP-25-01275

Ref. 983. Topalian AG, et al. (2026) Fam Med Community Health, 14. Available from: https://doi.org/10.1136/fmch-2025-003707

Ref. 984. Mollica MA, et al. (2024) J Cancer Surviv, 18: 1190. Available from: https://doi.org/10.1007/s11764-024-01602-6

Ref. 985. Manne S, et al. (2024) J Cancer Surviv, 18: 1. Available from: https://doi.org/10.1007/s11764-023-01528-5

Ref. 986. Howell D, et al. (2015) Ann Oncol, 26: 1846. Available from: https://doi.org/10.1093/annonc/mdv181

Ref. 987. Xia Y, et al. (2025) NPJ Digit Med, 8: 399. Available from: https://doi.org/10.1038/s41746-025-01812-x.

Ref. 988. Rocque GB, et al. (2025) JAMA Netw Open, 8: e259852. Available from: https://doi.org/10.1001/jamanetworkopen.2025.9852

Ref. 989. Dupuis LL, et al. (2024) JAMA, 332: 1981. Available from: https://doi.org/10.1001/jama.2024.19585

Ref. 990. Basch E, et al. (2025) Nat Med, 31: 1225. Available from: https://doi.org/10.1038/s41591-025-03507-y

Ref. 991. Dussel V, et al. (2026) J Clin Oncol, 44: 685. Available from: https://doi.org/10.1200/JCO-25-01036

Ref. 992. Huang RS, et al. (2025) JAMA Oncol, 11: 1303. Available from: https://doi.org/10.1001/jamaoncol.2025.3153

Ref. 993. Colbert JA, et al. (2025) JAMA Oncol, 11: 233. Available from: https://doi.org/10.1001/jamaoncol.2024.6157

Ref. 994. AARP. Caregiving in the US. Accessed: June 30, 2026. Available from: https://www.aarp.org/content/dam/aarp/ppi/topics/ltss/family-caregiving/caregiving-in-us-2025.doi.10.26419-2fppi.00373.001.pdf

Ref. 995. Odom JN, et al. (2026) Support Care Cancer, 34. Available from: https://doi.org/10.1007/s00520-026-10500-9

Ref. 996. Choudry MM, et al. (2024) Cancer, 130: 4061. Available from: https://doi.org/10.1002/cncr.35486

Ref. 997. Klekovkina E, et al. (2025) Archives of Gerontology and Geriatrics Plus, 2: 100141. Available from: https://doi.org/10.1016/j.aggp.2025.100141

Ref. 998. Zhu XY, et al. (2026) Ann Med, 58: 2624214. Available from: https://doi.org/10.1080/07853890.2026.2624214

Ref. 999. Segrin C, et al. (2025) J Psychosoc Oncol, 43: 574. Available from: https://doi.org/10.1080/07347332.2025.2450012

Ref. 1000. Anant S, et al. (2025) JCO Oncol Pract, 21: 41. Available from: https://doi.org/10.1200/OP.24.00305

Ref. 1001. Wang Q, et al. (2024) J Cancer Surviv, 18: 553. Available from: https://doi.org/10.1007/s11764-022-01265-1

Ref. 1002. Mahmood A, et al. (2025) Support Care Cancer, 33: 75. Available from: https://doi.org/10.1007/s00520-024-09133-7

Ref. 1003. Wang Q, et al. (2026) JCO Oncol Pract, 22: 1096. Available from: https://doi.org/10.1200/OP-25-00388

Ref. 1004. Administration for Community Living. 2022 National Strategy to Support Family Caregivers. Accessed: June 30, 2026. Available from: https://acl.gov/sites/default/files/RAISE_SGRG/NatlStrategyToSupportFamilyCaregivers-2.pdf

Ref. 1005. Odom JN, et al. (2023) JAMA Netw Open, 6: e2337250. Available from: https://doi.org/10.1001/jamanetworkopen.2023.37250

Ref. 1006. Pak M, et al. (2026) Cell Genom, 6: 101036. Available from: https://doi.org/10.1016/j.xgen.2025.101036

Ref. 1007. Wang D, et al. (2026) Nat Rev Drug Discov, 25: 204. Available from: https://doi.org/10.1038/s41573-025-01317-y

Ref. 1008. Ehlen L, et al. (2026) Nat Biomed Eng, 10: 815. Available from: https://doi.org/10.1038/s41551-025-01594-3

Ref. 1009. Du L, et al. (2025) Mol Cancer, 24: 259. Available from: https://doi.org/10.1186/s12943-025-02466-9

Ref. 1010. Valanarasu JMJ, et al. (2026) Cell, 189: 386. Available from: https://doi.org/10.1016/j.cell.2025.11.016

Ref. 1011. Kundal K, et al. (2025) NPJ Precis Oncol, 9: 323. Available from: https://doi.org/10.1038/s41698-025-01124-z

Ref. 1012. Alves N, et al. (2026) Lancet Oncol, 27: 116. Available from: https://doi.org/10.1016/s1470-2045(25)00567-4

Ref. 1013. Gao Z, et al. (2025) Nat Cancer, 6: 2025. Available from: https://doi.org/10.1038/s43018-025-01060-8

Ref. 1014. Olson KD, et al. (2025) JAMA Netw Open, 8: e2534976. Available from: https://doi.org/10.1001/jamanetworkopen.2025.34976

Ref. 1015. Jia Y, et al. (2026) Science, 391: eads9530. Available from: https://doi.org/10.1126/science.ads9530

Ref. 1016. Kim H, et al. (2025) Nat Commun, 16: 5628. Available from: https://doi.org/10.1038/s41467-025-60763-9

Ref. 1017. Sinha S, et al. (2025) NPJ Precis Oncol, 9: 340. Available from: https://doi.org/10.1038/s41698-025-01111-4

Ref. 1018. Wright WC, et al. (2025) Nat Commun, 16: 11005. Available from: https://doi.org/10.1038/s41467-025-66223-8

Ref. 1019. More V, et al. (2026) NPJ Precis Oncol, 10. Available from: https://doi.org/10.1038/s41698-025-01265-1

Ref. 1020. Kernbach JM, et al. (2025) NPJ Precis Oncol, 9: 387. Available from: https://doi.org/10.1038/s41698-025-01183-2

Ref. 1021. Azari F, et al. (2026) JAMA Netw Open, 9: e2551734. Available from: https://doi.org/10.1001/jamanetworkopen.2025.51734

Ref. 1022. Yu L, et al. (2025) Nat Commun, 17: 867. Available from: https://doi.org/10.1038/s41467-025-67581-z

Ref. 1023. Jeong J, et al. (2026) Exp Mol Med, 58: 1589. Available from: https://doi.org/10.1038/s12276-026-01718-y

Ref. 1024. Nenadic I, et al. (2026) Nat Med, 32: 1172. Available from: https://doi.org/10.1038/s41591-026-04215-x

Ref. 1025. Tsui WHA, et al. (2025) Cancer Cell, 43: 1792. Available from: https://doi.org/10.1016/j.ccell.2025.09.006

Ref. 1026. Hazelaar DM, et al. (2025) NPJ Precis Oncol, 10: 27. Available from: https://doi.org/10.1038/s41698-025-01237-5

Ref. 1027. Bao H, et al. (2025) Nat Med, 31: 2737. Available from: https://doi.org/10.1038/s41591-025-03735-2

Ref. 1028. Gouda MA, et al. (2025) Clin Cancer Res, 31: 4299. Available from: https://doi.org/10.1158/1078-0432.Ccr-24-3531

Ref. 1029. Botticelli A, et al. (2026) Clin Cancer Res, 32: 45. Available from: https://doi.org/10.1158/1078-0432.Ccr-25-0430

Ref. 1030. Sun X, et al. (2026) Sci Transl Med, 18: eaec2358. Available from: https://doi.org/10.1126/scitranslmed.aec2358

Ref. 1031. Shen Y, et al. (2026) Clin Cancer Res, 32: 1293. Available from: https://doi.org/10.1158/1078-0432.Ccr-25-3774

Ref. 1032. Brighi N, et al. (2025) Clin Cancer Res, 31: 4985. Available from: https://doi.org/10.1158/1078-0432.Ccr-25-2121

Ref. 1033. Powles T, et al. (2025) N Engl J Med, 393: 2395. Available from: https://doi.org/10.1056/NEJMoa2511885

Ref. 1034. Tie J, et al. (2025) Nat Med, 31: 4291. Available from: https://doi.org/10.1038/s41591-025-04030-w

Ref. 1035. Ansstas G, et al. (2026) Clin Cancer Res, 32: 1513. Available from: https://doi.org/10.1158/1078-0432.Ccr-25-3643

Ref. 1036. Landon BV, et al. (2025) Nat Med, 31: 4006. Available from: https://doi.org/10.1038/s41591-025-04093-9

Ref. 1037. Gomerdinger VF, et al. (2025) Nat Rev Cancer, 25: 657. Available from: https://doi.org/10.1038/s41568-025-00847-2

Ref. 1038. Lin Y, et al. (2026) Nat Mater, 25: 133. Available from: https://doi.org/10.1038/s41563-025-02320-9

Ref. 1039. Martini DJ, et al. (2025) Cancer Discov, 15: 1315. Available from: https://doi.org/10.1158/2159-8290.Cd-25-0300

Ref. 1040. Khattak A, et al. (2026) J Clin Oncol: 101200jco2600835. Available from: https://doi.org/10.1200/jco-26-00835

Ref. 1041. Sahin U, et al. (2026) Nature, 651: 1088. Available from: https://doi.org/10.1038/s41586-025-10004-2

Ref. 1042. Garfinkle EAR, et al. (2026) Nat Cancer. Available from: https://doi.org/10.1038/s43018-026-01163-w

Ref. 1043. Wang S, et al. (2025) Nat Rev Drug Discov, 24: 828. Available from: https://doi.org/10.1038/s41573-025-01237-x

Ref. 1044. Yan Y, et al. (2025) Mol Cancer, 24: 251. Available from: https://doi.org/10.1186/s12943-025-02463-y

Ref. 1045. Ju J (2025) Cell Rep Med, 6: 102057. Available from: https://doi.org/10.1016/j.xcrm.2025.102057

Ref. 1046. Niu D, et al. (2026) Mol Cancer Ther, 25: 272. Available from: https://doi.org/10.1158/1535-7163.Mct-25-0356

Ref. 1047. Quijano E, et al. (2025) Sci Transl Med, 17: eadk1868. Available from: https://doi.org/10.1126/scitranslmed.adk1868

Ref. 1048. Gomez LE, et al. (2019) Journal of the National Medical Association, 111: 383. Available from: https://doi.org/10.1016/j.jnma.2019.01.006

Ref. 1049. Woodcock A, et al. (2026) Science Advances, 12: eaeh0739. Available from: https://doi.org/doi:10.1126/sciadv.aeh0739

Ref. 1050. US Food and Drug Administration. FDA at a Glance 2023. Accessed: June 30, 2026. Available from: https://www.fda.gov/media/176816/download

Ref. 1051. National Public Radio. Former FDA Commissioner Scott Gottlieb on the resignation of Marty Makary. Accessed: June 30, 2026. Available from: https://www.npr.org/2026/05/13/nx-s1-5819897/former-fda-commissioner-scott-gottlieb-on-the-resignation-of-marty-makary

Ref. 1052. Insights. 13 Center Directors Across CDER, CBER In 17 Months … And Counting. Accessed: June 30, 2026. Available from: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/13-center-directors-across-cder-cber-in-17-months-and-counting-WFYVLZPFOBEN3IICCDM5LSKWZU/

Ref. 1053. US Food and Drug Administration. 2025 | OCE Annual Report. Accessed: June 30, 2026. Available from: https://www.fda.gov/media/193140/download?attachment

Ref. 1054. US Food and Drug Administration. FDA Patient-Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient’s Voice in Medical Product Development and Regulatory Decision Making. Accessed: June 30, 2026. Available from: https://www.fda.gov/drugs/development-approval-process-drugs/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical

Ref. 1055. US Food and Drug Administration. FDA WORKSHOP: 10th Annual Clinical Outcome Assessment in Cancer Clinical Trials Workshop OCTOBER 8, 2025 – 10/08/2025. Accessed: June 30, 2026. Available from: https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/fda-workshop-10th-annual-clinical-outcome-assessment-cancer-clinical-trials-workshop-october-8-2025

Ref. 1056. Blackstone EC, et al. (2025) J Clin Oncol, 43: 1176. Available from: https://doi.org/10.1200/JCO-24-02021

Ref. 1057. US Food and Drug Administration. Quantitative Systems Pharmacology (QSP)-Based Dose Selection for Minimum Anticipated Biological Effect Level (MABEL) in First-in-Human (FIH) Trials. Accessed: June 30, 2026. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quantitative-systems-pharmacology-qsp-based-dose-selection-minimum-anticipated-biological-effect

Ref. 1058. US Food and Drug Administration. Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development. Accessed: June 30, 2026. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/oncology-therapeutic-radiopharmaceuticals-dosage-optimization-during-clinical-development

Ref. 1059. US Food and Drug Administration. Development of Cancer Drugs for Use in Novel Combination – Determining the Contribution of the Individual Drugs’ Effects. Accessed: June 30, 2026. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-cancer-drugs-use-novel-combination-determining-contribution-individual-drugs-effects

Ref. 1060. Friends of Cancer Research. Assessing Contribution of Effect (COE) in Oncology Combination Therapies: Lessons Learned to Inform and Optimize Future Registrational Trial Designs. Accessed: June 30, 2026. Available from: https://friendsofcancerresearch.org/wp-content/uploads/Assessing-Contribution-of-Effect-COE-in-Oncology-Combination-Therapies-Lessons-Learned-to-Inform-and-Optimize-Future-Registrational-Trial-Designs.pdf

Ref. 1061. Precision for Medicine. Biomarker-Driven Clinical Trials in Oncology: Enrichment, Stratification, All-Comers & Basket. Accessed: June 30, 2026. Available from: https://www.precisionformedicine.com/blog/biomarker-driven-clinical-trials-in-oncology-enrichment-stratification-all-comers-basket-when-to-use-what-and-why

Ref. 1062. Vo TT, et al. (2025) Clin Cancer Res, 31: 4396. Available from: https://doi.org/10.1158/1078-0432.CCR-25-1255

Ref. 1063. Haslam A, et al. (2025) Journal of the American Geriatrics Society, 73: 3655. Available from: https://doi.org/10.1111/jgs.70000

Ref. 1064. US Food and Drug Administration. Enhancing Participation in Clinical Trials — Eligibility Criteria, Enrollment Practices, and Trial Designs. Accessed: June 30, 2026. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhancing-participation-clinical-trials-eligibility-criteria-enrollment-practices-and-trial-designs

Ref. 1065. US Food and Drug Administration. July 17, 2025: Meeting of the Oncologic Drugs Advisory Committee – 07/17/2025. Accessed: June 30, 2026. Available from: https://www.fda.gov/advisory-committees/july-17-2025-meeting-oncologic-drugs-advisory-committee-07172025

Ref. 1066. US Food and Drug Administration. FDA Eliminates Major Barrier to Using Real-World Evidence in Drug and Device Application Reviews. Accessed: June 30, 2026. Available from: https://www.fda.gov/news-events/press-announcements/fda-eliminates-major-barrier-using-real-world-evidence-drug-and-device-application-reviews

Ref. 1067. US Food and Drug Administration. The Future of Registries in Oncology. Accessed: June 30, 2026. Available from: https://www.fda.gov/industry/future-registries-oncology-08272025

Ref. 1068. US Food and Drug Administration. Accelerated Approval Program. Accessed: June 30, 2026. Available from: https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program

Ref. 1069. US Food and Drug Administration. Expedited Program for Serious Conditions — Accelerated Approval of Drugs and Biologics Guidance for Industry. Accessed: June 30, 2026. Available from: https://www.fda.gov/media/184120/download

Ref. 1070. American Association for Cancer Research. FDA-AACR Workshop: Approach to Novel Oncology Endpoint Development. Accessed: June 30, 2026. Available from: https://www.aacr.org/professionals/policy-and-advocacy/regulatory-science-and-policy/events/endpointsworkshop/

Ref. 1071. US Food and Drug Administration. Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval Guidance for Industry. Accessed: June 30, 2026. Available from: https://www.fda.gov/media/190647/download

Ref. 1072. Andrews HS, et al. (2025) J Immunother Cancer, 13. Available from: https://doi.org/10.1136/jitc-2025-012454

Ref. 1073. US Food and Drug Administration. Approaches to Assessment of Overall Survival in Oncology Clinical Trials Guidance for Industry. Accessed: June 30, 2026. Available from: https://www.fda.gov/media/188274/download

Ref. 1074. Lu R, et al. (2026) Statistics in Biopharmaceutical Research, 18: 215. Available from: https://doi.org/10.1080/19466315.2026.2641960

Ref. 1075. Forrest R, et al. (2026) JAMA Netw Open, 9: e2617450. Available from: https://doi.org/10.1001/jamanetworkopen.2026.17450

Ref. 1076. US Food and Drug Administration. Roadmap to Reducing Animal Testing in Preclinical Safety Studies. Accessed: June 30, 2026. Available from: https://www.fda.gov/media/186092/download

Ref. 1077. US Food and Drug Administration. FDA Releases Draft Guidance on Alternatives to Animal Testing in Drug Development. Accessed: June 30, 2026. Available from: https://www.fda.gov/news-events/press-announcements/fda-releases-draft-guidance-alternatives-animal-testing-drug-development

Ref. 1078. Seidler AL, et al. (2023) Med J Aust, 219: 192. Available from: https://doi.org/10.5694/mja2.52059

Ref. 1079. National Security Commission on Emergency Biotechnology. Report Summary: Charting the Future of Biotechnology. Accessed: June 30, 2026. Available from: https://www.biotech.senate.gov/wp-content/uploads/2026/06/NSCEB-Full-Report-–-Single-Pg-–-June-2026.pdf

Ref. 1080. US Food and Drug Administration. Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products Guidance for Industry. Accessed: June 30, 2026. Available from: https://www.fda.gov/media/190505/download

Ref. 1081. US Food and Drug Adiministration. FDA Announces Major Steps to Implement Real-Time Clinical Trials. Accessed: June 30, 2026. Available from: https://www.fda.gov/news-events/press-announcements/fda-announces-major-steps-implement-real-time-clinical-trials

Ref. 1082. US Department of Human and Health Services. HHS Launches Unprecedented Department-Wide Effort to Restore American Leadership in Clinical Trials. Accessed: June 30, 2026. Available from: https://www.hhs.gov/press-room/hhs-launches-clinical-trials-reform-initiative.html

Ref. 1083. Federal Register. Expedited Investigational New Drug Pilot Program; Request for Information. Accessed: June 30, 2026. Available from: https://www.federalregister.gov/documents/2026/06/24/2026-12621/expedited-investigational-new-drug-pilot-program-request-for-information

Ref. 1084. US Food and Drug Administration. International Regulatory Harmonization. Accessed: June 30, 2026. Available from: https://www.fda.gov/drugs/cder-international-program/international-regulatory-harmonization

Ref. 1085. US Food and Drug Administration. M15 General Principles for Model-Informed Drug Development. Accessed: June 30, 2026. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m15-general-principles-model-informed-drug-development

Ref. 1086. US Food and Drug Administration. M11 Clinical Electronic Structured Harmonised Protocol. Accessed: June 30, 2026. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m11-clinical-electronic-structured-harmonised-protocol

Ref. 1087. Center for Drug Evaluation and Research. E20 Adaptive Designs for Clinical Trials. Accessed: June 30, 2026. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e20-adaptive-designs-clinical-trials

Ref. 1088. US Food and Drug Administration. Statement of Cooperation Between the United States Food and Drug Administration and the African Medicines Agency Regarding Cooperation to Enhance Activities of Mututal Interest. Accessed: June 30, 2026. Available from: https://www.fda.gov/media/193118/download?attachment

Ref. 1089. GOV.UK. Unique liaison programme set to reinforce close collaboration between MHRA and FDA. Accessed: June 30, 2026. Available from: https://www.gov.uk/government/news/unique-liaison-programme-set-to-reinforce-close-collaboration-between-mhra-and-fda

Ref. 1090. US Food and Drug Administration. Center for Drug Evaluation and Researc. Guiding Principles of Good AI Practice in Drug Development. Accessed: June 30, 2026. Available from: https://www.fda.gov/about-fda/artificial-intelligence-drug-development/guiding-principles-good-ai-practice-drug-development

Ref. 1091. US Food and Drug Administration. Project Orbis. Accessed: June 30, 2026. Available from: https://www.fda.gov/about-fda/oncology-center-excellence/project-orbis

Ref. 1092. Bortolot M, et al. (2026) American Society of Clinical Oncology Educational Book, 46: e517100. Available from: https://doi.org/10.1200/EDBK-26-517100

Ref. 1093. Ge AY, et al. (2026) Blood, 147: 1521. Available from: https://doi.org/10.1182/blood.2025030872

Ref. 1094. Langselius O, et al. (2026) Lancet Glob Health, 14: e356. Available from: https://doi.org/10.1016/S2214-109X(25)00494-2

Ref. 1095. Congress.gov. H.R.842 – 119th Congress (2025-2026): Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act. Accessed: June 30, 2026. Available from: https://www.congress.gov/bill/119th-congress/house-bill/842

Ref. 1096. Congress.gov. H.R.2381 – SCREENS for Cancer Act of 2025. Accessed: June 30, 2026. Available from: https://www.congress.gov/bill/119th-congress/house-bill/2381

Ref. 1097. Congress.gov. S.1866 – 119th Congress (2025-2026): SCREENS for Cancer Act of 2025. Accessed: June 30, 2026. Available from: https://www.congress.gov/bill/119th-congress/senate-bill/1866

Ref. 1098. Congress.gov. H.R.6182 – 119th Congress (2025-2026): Find It Early Act. Accessed: June 30, 2026. Available from: https://www.congress.gov/bill/119th-congress/house-bill/6182

Ref. 1099. Congress.gov. H.R.6178 – 119th Congress (2025-2026): Increasing Access to Lung Cancer Screening Act. Accessed: June 30, 2026. Available from: https://www.congress.gov/bill/119th-congress/house-bill/6178

Ref. 1100. Congress.gov. S.4566 – 119th Congress (2025-2026): Increasing Access to Lung Cancer Screening Act. Accessed: June 30, 2026. Available from: https://www.congress.gov/bill/119th-congress/senate-bill/4566

Ref. 1101. KFF. Cancer-Related Preventive Health Services for Adults Covered by the ACA. Accessed: June 30, 2026. Available from: https://www.kff.org/affordable-care-act/cancer-related-preventive-services-covered-by-the-aca/

Ref. 1102. KFF. ACA Marketplace Premium Payments Would More than Double on Average Next Year if Enhanced Premium Tax Credits Expire. Accessed: June 30, 2026. Available from: https://www.kff.org/affordable-care-act/aca-marketplace-premium-payments-would-more-than-double-on-average-next-year-if-enhanced-premium-tax-credits-expire/

Ref. 1103. Congress.gov. Enhanced Premium Tax Credit and 2026 Exchange Premiums: Frequently Asked Questions. Accessed: June 30, 2026. Available from: https://www.congress.gov/crs-product/R48290

Ref. 1104. Congress.gov. Text – H.R.1 – 119th Congress (2025-2026): An act to provide for reconciliation pursuant to title II of H. Con. Res. 14. Accessed: June 30, 2026. Available from: https://www.congress.gov/bill/119th-congress/house-bill/1/text

Ref. 1105. KFF. A Closer Look at the Work Requirement Provisions in the 2025 Federal Budget Reconciliation Law. Accessed: June 30, 2026. Available from: https://www.kff.org/medicaid/a-closer-look-at-the-work-requirement-provisions-in-the-2025-federal-budget-reconciliation-law/

Ref. 1106. United States Preventive Services Taskforce. Draft Recommendation: Cervical Cancer: Screening. Accessed: June 30, 2026. Available from: https://www.uspreventiveservicestaskforce.org/uspstf/draft-recommendation/cervical-cancer-screening-adults-adolescents

Ref. 1107. Reuters. US postpones third consecutive meeting of preventive health panel. Accessed: June 30, 2026. Available from: https://www.reuters.com/business/healthcare-pharmaceuticals/march-meeting-us-preventive-services-task-force-postponed-2026-03-03/

Ref. 1108. Reuters. US Health Secretary Kennedy fires heads of key preventive health panel. Accessed: June 30, 2026. Available from: https://www.reuters.com/world/us-health-secretary-kennedy-fires-heads-key-preventive-health-panel-2026-05-20/

Ref. 1109. Human Resources and Services Administration. New Cervical Cancer Screening Guidelines Strengthen Women’s Preventive Health. Accessed: June 30, 2026. Available from: https://www.hrsa.gov/about/news/press-releases/new-cervical-cancer-screening-guidelines

Ref. 1110. Qin J, et al. (2026) Obstet Gynecol, 147: 306. Available from: https://doi.org/10.1097/AOG.0000000000006147

Ref. 1111. Green BB, et al. (2026) NEJM Catalyst, 7: CAT.25.0420. Available from: https://doi.org/10.1056/CAT.25.0420

Ref. 1112. National Cancer Institute. HPV Tests with Self-Collection in a Health Setting Approved. Accessed: June 30, 2026. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2024/fda-hpv-test-self-collection-health-care-setting

Ref. 1113. PRNewswire. FDA Approves Teal Health’s Teal Wand™–The First and Only At-Home Self-Collection Device for Cervical Cancer Screening, Introducing a Comfortable Alternative to In-Person Screening. Accessed: June 30, 2026. Available from: https://www.prnewswire.com/news-releases/fda-approves-teal-healths-teal-wandthe-first-and-only-at-home-self-collection-device-for-cervical-cancer-screening-introducing-a-comfortable-alternative-to-in-person-screening-302451189.html

Ref. 1114. Targeted Oncology. NCCN Updates Breast Cancer Guidelines to Include AI-Based Risk Assessment. Accessed: June 30, 2026. Available from: https://www.targetedonc.com/view/nccn-updates-breast-cancer-guidelines-to-include-ai-based-risk-assessment

Ref. 1115. Centers for Disease Control and Prevention. Cancer Screening Change Packages. Accessed: June 30, 2026. Available from: https://www.cdc.gov/cancer/media/pdf/change-packages-overview-v2-508.pdf

Ref. 1116. Centers for Disease Control and Prevention. NIOSH List of Hazardous Drugs in Healthcare Settings, 2024. Accessed: June 30, 2026. Available from: https://www.cdc.gov/niosh/publications/hcp/numbered/2025-103.html

Ref. 1117. The White House. Aligning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries. Accessed: June 30, 2026. Available from: https://www.whitehouse.gov/presidential-actions/2025/12/aligning-united-states-core-childhood-vaccine-recommendations-with-best-practices-from-peer-developed-countries/

Ref. 1118. Centers for Disease Control and Prevention. CDC Acts on Presidential Memorandum to Update Childhood Immunization Schedule. Accessed: June 30, 2026. Available from: https://www.cdc.gov/media/releases/2026/2026-cdc-acts-on-presidential-memorandum-to-update-childhood-immunization-schedule.html

Ref. 1119. American Association for Cancer Research. Cancer Policy Monitor: July 8, 2025. Accessed: June 30, 2026. Available from: https://www.aacr.org/professionals/policy-and-advocacy/aacr-cancer-policy-monitor/cancer-policy-monitor-july-8-2025/

Ref. 1120. Burger EA, et al. (2026) Lancet Reg Health Am, 55: 101361. Available from: https://doi.org/10.1016/j.lana.2025.101361

Ref. 1121. Society of Gynecologic Oncology. The New U.S. Childhood Vaccine Schedule: A Key Change for HPV Immunization. Accessed: June 30, 2026. Available from: https://www.sgo.org/news/the-new-u-s-childhood-vaccine-schedule-a-key-change-for-hpv-immunization/

Ref. 1122. KFF. State Recommendations for Routine Childhood Vaccines: Increasing Departure from Federal Guidelines. Accessed: June 30, 2026. Available from: https://www.kff.org/state-health-policy-data/state-recommendations-for-routine-childhood-vaccines-increasing-departure-from-federal-guidelines/

Ref. 1123. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC) Human Papillomavirus (HPV) Vaccine Workgroup. Accessed: June 30, 2026. Available from: https://www.cdc.gov/acip/downloads/hpv-tor-508.pdf

Ref. 1124. National Public Radio. Federal judge halts RFK Jr.’s changes to children’s vaccine policies. Accessed: June 30, 2026. Available from: https://www.npr.org/2026/03/16/nx-s1-5749530/judge-blocks-rfk-jr-vaccine-changes

Ref. 1125. US Department of Health and Human Services. Alcohol and Cancer Risk. Accessed: June 30, 2026. Available from: https://www.hhs.gov/surgeongeneral/reports-and-publications/alcohol-cancer/index.html

Ref. 1126. MultiState. Alcohol Legislation Takes A New Turn: Canned Cocktails, Direct-to-Consumer Shipping, and More. Accessed: June 30, 2026. Available from: https://www.multistate.us/insider/2026/2/12/alcohol-legislation-takes-a-new-turn-canned-cocktails-direct-to-consumer-shipping-and-more

Ref. 1127. Federal Registrar. General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; Withdrawal of Proposed Rule. Accessed: June 30, 2026. Available from: https://public-inspection.federalregister.gov/2026-05103.pdf

Ref. 1128. Centers for Disease Control and Prevention. Reducing Risk for Skin Cancer. Accessed: June 30, 2026. Available from: https://www.cdc.gov/skin-cancer/prevention/index.html

Ref. 1129. Centers for Disease Control and Prevention. Community Strategies to Lower Skin Cancer Risk. Accessed: June 30, 2026. Available from: https://www.cdc.gov/skin-cancer/php/community-strategies/index.html

Ref. 1130. Do EK, et al. (2025) Preventive Medicine Reports: 103284. Available from: https://doi.org/10.1016/j.pmedr.2025.103284

Ref. 1131. Patel M, et al. (2026) American Journal of Preventive Medicine, 70: 108160. Available from: https://doi.org/10.1016/j.amepre.2025.108160

Ref. 1132. Truth Initiative. What federal health agency cuts mean for tobacco control. Accessed: June 30, 2026. Available from: https://truthinitiative.org/FederalCuts

Ref. 1133. Bold KW, et al. (2024) Annu Rev Clin Psychol, 20: 381. Available from: https://doi.org/10.1146/annurev-clinpsy-080921-075624

Ref. 1134. US Food and Drug Administration. FDA Expands Market Access, Authorizes New ENDS Products. Accessed: June 30, 2026. Available from: https://www.fda.gov/news-events/press-announcements/fda-expands-market-access-authorizes-new-ends-products

Ref. 1135. US Food and Drug Administration. FDA Authorizes Marketing of Tobacco- and Menthol-Flavored JUUL E-Cigarette Products. Accessed: June 30, 2026. Available from: https://www.fda.gov/tobacco-products/ctp-newsroom/fda-authorizes-marketing-tobacco-and-menthol-flavored-juul-e-cigarette-products

Ref. 1136. US Food and Drug Administration. Flavored Electronic Nicotine Delivery Systems (ENDS) Premarket Applications – Considerations Related to Youth Risk. Accessed: June 30, 2026. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/flavored-electronic-nicotine-delivery-systems-ends-premarket-applications-considerations-related

Ref. 1137. Leigh NJ, et al. (2016) Tob Control, 25: ii81. Available from: https://doi.org/10.1136/tobaccocontrol-2016-053205

Ref. 1138. Erhabor J, et al. (2025) Nicotine Tob Res, 27: 1651. Available from: https://doi.org/10.1093/ntr/ntaf067

Ref. 1139. Mohapatra S, et al. (2025) ESMO Open, 10: 105910. Available from: https://doi.org/10.1016/j.esmoop.2025.105910

Ref. 1140. Sachdeva J, et al. (2023) Cureus, 15: e48995. Available from: https://doi.org/10.7759/cureus.48995

Ref. 1141. Livingstone-Banks J, et al. (2025) Addiction, 120: 1327. Available from: https://doi.org/10.1111/add.70017

Ref. 1142. US Food and Drug Administration. Justice Department and FDA Announce Federal Multi-Agency Task Force to Curb the Distribution and Sale of Illegal E-Cigarettes. Accessed: June 30, 2026. Available from: https://www.fda.gov/news-events/press-announcements/justice-department-and-fda-announce-federal-multi-agency-task-force-curb-distribution-and-sale

Ref. 1143. Congress.gov. S.3569 – 119th Congress (2025-2026): S.T.O.P. Illicit Vapes Act. Accessed: June 30, 2026. Available from: https://www.congress.gov/bill/119th-congress/senate-bill/3569

Ref. 1144. US Food and Drug Administration. FDA Issues Guidance on Enforcement Priorities for Unauthorized ENDS and Nicotine Pouch Products. Accessed: June 30, 2026. Available from: https://www.fda.gov/tobacco-products/ctp-newsroom/fda-issues-guidance-enforcement-priorities-unauthorized-ends-and-nicotine-pouch-products

Ref. 1145. US Food and Drug Administration. FDA Makes Determinations On More Than 99% of the 26 Million Tobacco Products For Which Applications Were Submitted. Accessed: June 30, 2026. Available from: https://www.fda.gov/tobacco-products/ctp-newsroom/fda-makes-determinations-more-99-26-million-tobacco-products-which-applications-were-submitted

Ref. 1146. Congress.gov. S.4257 – 119th Congress (2025-2026): Resources To Prevent Youth Vaping Act. Accessed: June 30, 2026. Available from: https://www.congress.gov/bill/119th-congress/senate-bill/4257

Ref. 1147. Campaign for Tobacco-Free Kids. Reinstatement of Staff at FDA Center for Tobacco Products Is a Positive Step for Public Health. Accessed: June 30, 2026. Available from: https://www.tobaccofreekids.org/press-releases/2026_03_30_reinstatement-of-staff-at-fda-center-for-tobacco-products-is-a-positive-step-for-public-health

Ref. 1148. US Food and Drug Administration. FDA Adds 18 Constituents to the List of Harmful and Potentially Harmful Constituents, Seeks Comment on Three Additional Constituents. Accessed: June 30, 2026. Available from: https://www.fda.gov/tobacco-products/ctp-newsroom/fda-adds-18-constituents-list-harmful-and-potentially-harmful-constituents-seeks-comment-three

Ref. 1149. US Food and Drug Administration. A Statement From FDA Commissioner Marty Makary, M.D., M.P.H.: Encouraging Retailers to Stop Selling Illegal Vapes. Accessed: June 30, 2026. Available from: https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-marty-makary-md-mph-encouraging-retailers-stop-selling-illegal-vapes

Ref. 1150. US Food and Drug Administration. FDA Warns Retailers Selling Illegal Tobacco Products That Look Like Everyday Products. Accessed: June 30, 2026. Available from: https://www.fda.gov/news-events/press-announcements/fda-warns-retailers-selling-illegal-tobacco-products-look-everyday-products

Ref. 1151. National Institutes of Health. NOT-OD-26-045: Notice of Information Encouraging Submission of Pre-Application Consultation Information for RFA-OD-25-008, “Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional)”. Accessed: June 30, 2026. Available from: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-26-045.html

Ref. 1152. US Food and Drug Administration. Tobacco Centers of Regulatory Science (TCORS). Accessed: June 30, 2026. Available from: https://www.fda.gov/tobacco-products/research/tobacco-centers-regulatory-science-tcors

Ref. 1153. US Food and Drug Administration. The Real Cost Campaign. Accessed: June 30, 2026. Available from: https://www.fda.gov/tobacco-products/public-health-education-campaigns/real-cost-campaign

Ref. 1154. US Food and Drug Administration. Studies Show FDA Educational Efforts Help Prevent Youth From Starting E-Cigarette Use, Illegal E-Cigarette Sales. Accessed: June 30, 2026. Available from: https://www.fda.gov/tobacco-products/ctp-newsroom/studies-show-fda-educational-efforts-help-prevent-youth-starting-e-cigarette-use-illegal-e-cigarette

Ref. 1155. MacMonegle A, et al. (2026) Am J Prev Med, 70: 107614. Available from: https://doi.org/10.1016/j.amepre.2025.02.015

Ref. 1156. Koplow B (2026) Am J Prev Med, 70: 108422. Available from: https://doi.org/10.1016/j.amepre.2026.108422

Ref. 1157. Centers for Disease Control and Prevention. Tips Impact and Results – Tips for former Smokers. Accessed: June 30, 2026. Available from: https://www.cdc.gov/tobacco/campaign/tips/about/impact/campaign-impact-results.html

Ref. 1158. Centers for Disease Control and Prevention. OSH Partners With States. Accessed: June 30, 2026. Available from: https://www.cdc.gov/tobacco/programs/osh-partners-with-states.html

Ref. 1159. American Association for Cancer Research. Tobacco Prevention and Control is a Crucial Strategy in Combating Chronic Disease. Accessed: June 30, 2026. Available from: https://www.aacr.org/professionals/policy-and-advocacy/science-policy-government-affairs/aacr-congressional-events/tobacco-prevention-and-control-is-a-crucial-strategy-in-combating-chronic-disease/

Ref. 1160. Environmental Protection Agency. Risk Assessment for Carcinogenic Effects. Accessed: June 30, 2026. Available from: https://www.epa.gov/fera/risk-assessment-carcinogenic-effects

Ref. 1161. Environmental Protection Network. FactSheet: Trump’s FY26 EPA Budget Proposal Puts Communities in Harm’s Way. Accessed: June 30, 2026. Available from: https://www.environmentalprotectionnetwork.org/wp-content/uploads/2025/05/Trump-FY26-EPA-Skinny-Budget-Factsheet.pdf

Ref. 1162. Environmental Protection Agency. Final Rule: Rescission of the Greenhouse Gas Endangerment Finding and Motor Vehicle Greenhouse Gas Emission Standards Under the Clean Air Act. Accessed: June 30, 2026. Available from: https://www.epa.gov/regulations-emissions-vehicles-and-engines/final-rule-rescission-greenhouse-gas-endangerment

Ref. 1163. Center for Biological Diversity. New Analyses: EPA Consistently Fails to Warn Public of Pesticide Cancer Risks. Accessed: June 30, 2026. Available from: https://biologicaldiversity.org/w/news/press-releases/new-analyses-epa-consistently-fails-to-warn-public-of-pesticide-cancer-risks-2026-03-30/

Ref. 1164. Congress.gov. H.R.8839 – 119th Congress (2025-2026): Lainie Jones Comprehensive Cancer Survivorship Act of 2026. Accessed: June 30, 2026. Available from: https://www.congress.gov/bill/119th-congress/house-bill/8839

Ref. 1165. Centers for Disease Control and Prevention. Cancer Survivorship Care Plans. Accessed: June 30, 2026. Available from: https://www.cdc.gov/cancer-survivors/life-after-cancer/survivorship-care-plans.html

Ref. 1166. Chu AK, et al. (2022) Curr Oncol, 29: 7343. Available from: https://doi.org/10.3390/curroncol29100577

Ref. 1167. National Academies of Sciences, Engineering, and Medicine. 2025. Rethinking Race and Ethnicity in Biomedical Research. Washington, DC: The National Academies Press. Available from: https://doi.org/https://doi.org/10.17226/27913

Ref. 1168. Brown I, et al. (2025) PLoS One, 20: e0332805. Available from: https://doi.org/10.1371/journal.pone.0332805

Ref. 1169. Office of the National Coordinator for Health Information Technology. HTI-1 Final Rule. Accessed: June 30, 2026. Available from: https://healthit.gov/regulations/hti-rules/hti-1-final-rule/

Ref. 1170. Office of the National Coordinator for Health Information Technology. HHS Expands Secure Access to Health Records Through the TEFCA® Network, Announces Milestone of One Billion Health Records Exchanged. Accessed: June 30, 2026. Available from: https://www.hhs.gov/press-room/onc-strengthens-tefca-one-billion-health-records-exchanged.html

Ref. 1171. National Cancer Institute. CCDI Progress. Accessed: June 30, 2026. Available from: https://www.cancer.gov/research/areas/childhood/childhood-cancer-data-initiative/progress

Ref. 1172. US Department of Health and Human Services. HHS Doubles AI-Backed Childhood Cancer Research Funding. Accessed: June 30, 2026. Available from: https://www.hhs.gov/press-room/hhs-doubles-ai-backed-childhood-cancer-research-funding.html